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ABSTRACT
SHAMI, RULA, T., Masters of Science June: 2020, Public Health 
Title: The Role of Qatar Community Pharmacists in Depression Care: A Survey of 
Attitudes, Practices and Percieved Barriers 
Supervisors of   Thesis: Dr Mohammad Fasihul-Alam and Dr Maguy El-Hajj. 
 
Background: Negative attitudes and stigma are considered to be major barriers to 
healthcare and quality of life around the world for patients with depression. Community 
pharmacists are one of the most accessible healthcare providers. They can enhance 
patients’ adherence to antidepressant regimens through counselling on depression and 
antidepressant medications, as well as the provision of adequate follow up and 
medication management. 
Aim: Our study aims to describe the current practices, attitudes and perceived barriers 
of Qatar community pharmacists in relation to the provision of depression care. 
Methods: This is a cross-sectional online survey targeting all practicing community 
pharmacists in Qatar using an adapted survey instrument. Responses were measured on 
a 5-point-Likert scale. Study outcomes were scores of attitudes to depression, scores of 
self-reported depression care practices and the number of perceived barriers. These 
scores were produced by summing the individual scores of a set of survey items under 
the domain used to assess each outcome.  Descriptive analyses of pharmacists’ 
responses were done using means and standard deviations for continuous variables, and 
frequency tables for categorical variables. Bivariate and multivariate regression 
analyses were also employed to investigate how pharmacists’ characteristics and 
attitude affected their practice. Statistical analysis was conducted using STATA version 
15.1 and assigned a p-value of 0.05 for statistical significance. 
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Results: The survey had a response rate of 39%. Pharmacists’ attitudes to depression 
were moderately positive. Out of a possible score of 5, the mean score of attitudes was 
3.41, with a standard deviation of 0.94. However, the extent of pharmacists’ 
involvement in depression care was very low. Out of a possible score of 5, pharmacists’ 
practices had a mean score of 2.64 and a standard deviation of 0.26. The top three 
reported barriers were the lack of access to patients' medical records (83.21%), lack of 
patients’ insight on major depression and the importance of treatment (81.85%) and the 
lack of needed knowledge and training on mental health (79.63%), respectively. Female 
pharmacists were significantly less involved in depression care compared to male 
pharmacists (p= 0.006). Depression practice score increased with an increasing score 
of attitudes (p =0.001), and decreased with the number of years since the last pharmacy 
degree graduation (p=0.02).The presence of a private area for counselling patients was 
associated with higher scores of practice (p=0.03). Pharmacists’ practice scores  varied  
across types of pharmacy setting, where pharmacists who worked in pharmacies located 
in shopping malls and supermarkets showed the highest scores of practice compared to 
community pharmacies of private hospitals (p=0.05). 
Conclusion: Pharmacists’ moderately positive attitudes towards depression and its care 
were not reflected in their current practices. A set of perceived barriers against the 
provision of depression care were also identified in this study. Results from this study 
could serve as an evidence base for future longitudinal studies in Qatar, implying a need 
for the development of local depression care and training programs for pharmacists to 
improve their knowledge and improve their attitude towards depression care. 
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CHAPTER 1: INTRODUCTION 
1.1 Depression and its burden: 
Mental disorders contribute to 14% of the global burden of diseases, of which 
depression is considered the most common type (1). Data from the World Health 
Organization (WHO) indicates that in 2015, 4.4% of the global population suffered 
from depression and the prevalence was higher in females (5.1%) than males (3.6%) 
(2).Unmet mental health need is a global challenge, as there is a documented gap 
between the need for treatment and its provision worldwide (3). As a result, depression 
remains to be a main contributor to mortality, (4-6) and a leading cause of disability 
worldwide (7). It is also a leading cause of exacerbation of other mental health 
problems, such as anxiety disorders, and physical health problems like coronary heart 
disease (CHD) (4-6). Studies have shown that major depression was associated with 
exacerbations and poorer outcomes of CHD, independently from its established risk 
factors like hypertension, diabetes mellitus and smoking (4-6). Depression has a strong 
effect on different aspects of a person’s life if remained undiagnosed (3, 8). 
Undiagnosed depression was found to be significantly correlated with psychological 
stress and drug use, which add   social costs that could be higher than of $100,000 per 
quality-adjusted-life year QALY (9). Several economic costs of having depression 
have also been listed in literature, such as higher need for medical care, lower quality 
of life, and lower productivity at workplace(8). 
“Major depressive disorder”, commonly referred to as “Depression” , is  a 
common mental disorder characterized by a set of symptoms that persist for not less 
than two weeks, and mainly include  sadness ,loss of interest in activities a person 
normally enjoys, and inability to perform daily activities. Depression is caused by 
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complex interactions occurring between psychological, biological and social factors. 
The effect of such interactions can be higher in presence of  life events such as stressful 
experiences during childhood or loss of employment (10). In terms of depression 
assessment, several effective screening tools were described in literature, such as Beck 
Depression Inventory, two-item or nine-item Physician Health Questionnaire PHQ-2 
and PHQ-9 (11). As for treatment of depression, the main interventions are cognitive 
behavioral therapy, brief psychotherapy and antidepressant medications, or any 
combination of these interventions depending on depression severity level ,the number 
of previous episodes and the previous response to a certain intervention (12, 13). 
Clinical guidelines for the treatment of major depression from The National Institute 
for Health and Care Excellence (NICE) recommend that antidepressants need to be 
taken for at least 3 to 4 weeks before ascertaining their efficacy. They also emphasize 
that treatment needs to be continued for at least 8 months after symptom remission in 
order to prevent relapse (13).The American Psychiatric Association (APA) guidelines 
indicate that 4–8 weeks of treatment are needed before making conclusions about 
patient’s responsiveness to antidepressant treatment (12). However, the low adherence 
to medical treatment of depression was found to be an area of concern, and a main 
cause of high relapse rates in patients who were initiated on antidepressant 
medications(5) .   
A review of community-based psychiatric  studies found that the median rates 
of  depression cases which remained untreated was 56.3% ,and represented a treatment 
gap that is almost twice the gap in treatment of schizophrenia and other affective 
disorders ( 32.2% )(14) . As a result, several mental health programs have been 
conducted worldwide, where major depression was set in the core of their defined 
priorities.  The mental health Gap Action Programme (mhGAP) developed by WHO 
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has emphasized the importance of the role of non-specialist health care providers, being 
part of the “the first-level facilities” which included general practitioners, nurses, 
pharmacists, community officers and midwives. It produced evidence-based guidance 
to enable them to better identify and manage depression (15, 16) .Qatar has seen a high 
increase in psychiatric morbidity (17), and a high prevalence of depression in primary 
health care setting (4). Strategies have been set to direct efforts towards increasing the 
delivery of healthcare for mental health in primary care and community settings. 
Hamad Medical Corporation (HMC) has established a number of community-based 
facilities, in order to expand community-based mental health services.  At national 
level, goals have also been set to act against stigma towards mental health  by creating 
community awareness on  depression as a disease that can be treated,  increasing the 
availability of high-quality services, and improving skills of mental health care 
providers (3). In that regards, HMC mental health services started providing continuing 
education in the field of mental health to non-specialized healthcare professionals (18).  
1.2 Community pharmacists’ role within primary healthcare: 
Found within the primary care, community pharmacy, also referred to as retail 
or private pharmacy sector, is a collective form of pharmacy practice that is centered 
within a community (19). In addition to their traditional role of medication dispensing, 
pharmacists practicing in community pharmacies can play a major role in health 
promotion and disease prevention (20), being the most accessible healthcare 
professionals whenever a patient seeks advice on health and self-care in general (16). 
Their role has been described to be multifaceted, and it has been evident that 
community pharmacists play varied roles. They are involved in the management of 
asthma, arthritis, osteoporosis ,cardiovascular diseases, diabetes, , hypertension, 
depression, and palliative care either alone or as part of a  disease management 
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team(21). However, available data on the practice of those roles is suspected to vary 
significantly across countries, and is confounded by the fact that most of the relevant 
literature is available mainly from the UK and USA (22, 23). A set of new extended 
practice roles changed the focus of community pharmacy practice  from being task-
oriented ; i.e., limited to medication dispensing, to a more patient-oriented profession 
that involves providing care, advice ,counseling and medication management (24).  
1.3 Pharmacy practice in Qatar: 
In Qatar, healthcare services are provided to all nationals and residents by a mix 
of public, private, and semi-governmental institutions. However, the public sector, as 
represented by HMC and PHCC remains to be the main healthcare provider in Qatar 
(25) . Health care provision by these two institutions has seen rapid expansion in the 
past years , specifically in relation to primary care services (25). There are 
approximately 2500 practicing pharmacists in Qatar. Around 1200 of these pharmacists 
work in community and outpatient hospital pharmacies of the private sector, while the 
remaining number work as either clinical pharmacists or outpatient ambulatory 
pharmacists in public primary health care centers and public hospitals(26). Both 
community and clinical pharmacists work under the umbrella of the Ministry of Public 
Health MoPH .All Qatar pharmacists are required to pass an initial examination in order 
to attain a practice license from Qatar Council of Healthcare Practitioners. They also 
need to attend a defined number of continuous professional development CDP activities 
annually in order to have their practice license renewed (27).  
In the community and ambulatory pharmacy sectors, practice is predominantly 
limited to dispensing of medications and pharmaceutical products (28). In Qatar, it is 
quite uncommon that pharmacists who work in this sector actively deliver 
pharmaceutical care, do medication therapy management or provide other extended 
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cognitive services. Qatar, as well as some other countries in the Gulf region, have 
developed several programs to enable community pharmacists to undertake extended 
counselling roles (20, 29, 30). 
The public hospital pharmacy sector currently provides ward-based clinical 
pharmacy services where, in addition to the standard inpatient and outpatient drug-
dispensing services, clinical pharmacists are exposed to an extensive level of patient-
centered professional practice and they are part of a multidisciplinary team. However, 
those clinical pharmacy services were only recently introduced and are limited to only 
some units of public hospitals intensive care, pediatrics, and oncology and, most 
recently, psychiatry units. Clinical pharmacists working in HMC Rumaila Hospital, 
which is the specialized public mental health hospital, play a set of defined roles with 
respect to mental health care. They participate clinical rounds, carry out psychotropic 
medication optimization, monitor medication safety as well as provide mental patients 
with education about their prescribed psychotropic medication regimens. (28, 31, 32). 
 
 
 
 
 
 
 
 
 
 
 
   
   
6 
CHAPTER 2: LITERATURE REVIEW 
2.1 Adherence to antidepressant medications: 
Low adherence to prescribed antidepressant regimens has always been 
mentioned as an area of concern that adversely affects depression treatment. 
Furthermore, depression itself is considered a significant risk factor for noncompliance 
to medication (33). A meta-analysis conducted by Dimatteo et al. that investigated the 
relationship between depression and adherence to treatment. It concluded that 
regardless of what medication was used; depressed patients were three times less likely 
to comply with treatment recommendations compared with non -depressed patients (34) 
. Literature has also shown that adherence to antidepressants and reduction of relapse 
required a combination of adequate treatment duration, realistic patient expectations, 
and use of the right dose of a drug that can act on a wide range of symptoms while 
maintaining a proper control of adverse effects (35).  
The reported relapse rate in patients prescribed antidepressants  was as high as 
80%, which is attributed to several factors, and one of  those major factors  was in-
adherence to treatment   (36). A study in the United States of America (USA) showed 
that patients with depression had high rates of relapse when up to 33% of them 
discontinued treatment within the first 30 days and 40 % of them within 90 days of 
antidepressant initiation (35, 37) . 
Patients reported a set of reasons or patient factors that may cause early 
discontinuation of antidepressants. These factors ranged between patients’ perceptions 
that symptoms of depression were eradicated, beliefs that medications were no more 
needed and doubts about medication efficacy and safety (33, 38). The latter 
antidepressant medication-related issues such as adverse effects and delayed onset of 
action can cause patients to prematurely drop the prescribed medication (39). On the 
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other hand, several psychosocial issues may lower levels of adherence as well as limit 
the provision of care (40, 41). Negative attitudes, misunderstanding, stigma and 
discrimination were shown to be major barriers to healthcare and quality of life around 
the world for people with depression. A national survey of 1300 patients with mental 
disorders in the USA revealed that patients suffered from high levels of stigmatizing 
behavior from society, and most importantly from their healthcare providers (42).  More 
than half of the respondents reported being offered discouraging advice and being 
treated with rejection from their health care provider (42). Other studies also showed 
that such negative attitudes of healthcare providers towards patients might eventually 
lead to failure in seeking treatment and support when the patient’s depression symptoms 
arise, and also indicate a suboptimal use of their prescribed medications (3, 5, 35).  
2.2 Depression and low adherence to treatment in primary care: 
In this context of depression and low adherence to treatment, it would be 
important to look at the case of the primary care sector, which is the main provider of 
healthcare services for patients with depression. Evidence from the literature suggests 
that most patients with mild to moderate depression receive their diagnoses and 
treatments from primary care physicians, with less need for referral to specialist care 
(4, 5, 43-45). In 2018, a study conducted in Germany investigated the health utilization 
patterns (rates of attendance, diagnoses, prescription and hospitalization) of patients 
with ICD-10 codes F45.0-F45 as defined by “Pain disorder with related psychological 
factors”. It concluded that patients with chronic diseases and those who suffer from 
depression were frequent or very frequent attenders in both in primary care and out-of-
hours health care at  significantly higher rates compared to the general study population 
who did not have the F45- diagnoses (45). The rates of attendances per 100 patients 
were 39.5 and 24.6 respectively. Additionally, this group of patients was shown to 
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suffer from major depression, but that usually remained under-reported (45).Moreover, 
general practitioners were described as gate-keepers of the specialized health care,  and 
that might possibly make them lack enough time to offer appropriate disease 
counselling medication and management to their patients (17, 36, 46) .  
Within the primary healthcare setting, in-adherence to antidepressant 
medications was described as being caused by either the patient factors, as described in 
the previous section or by healthcare provider factors (33). Several provider factors 
were reported in the literature such as  lack of the needed  knowledge of depression 
,suboptimal antidepressant dosing, lack of adequate information delivered to patients 
about their depression and antidepressant medication , lack of follow- up and 
monitoring of treatment efficacy, in addition to the provider’s low willingness to treat 
depression, or to monitor the  medication's effectiveness (33). Consequently, it was 
estimated that more than 80% of patients who were prescribed an antidepressant by a 
general practitioner reported not to receive the proper follow-up and monitoring of drug 
efficacy and safety (36, 46, 47). 
Thus, a major issue to consider is to what extent patients with depression are 
being offered the needed support, and whether they are being adequately educated on 
the importance of adhering to their prescribed antidepressant regimen. In this context, 
NICE guidelines for the treatment of severe depression emphasized collaborative 
patient-centered care which includes medication management as well as regular liaison 
with primary and secondary care practitioners (13). A systematic review of randomized 
controlled trials between 1982 and 2006 found conclusive evidence that changing 
systems of care delivery can improve the effectiveness of depression management in 
primary care (5). As per 2018 Australian and New Zealand guidelines on treatment of 
depression, in all patients who are diagnosed with moderate to severe depression, who 
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were initiated on antidepressants , and specifically those who did not respond fully to 
antidepressant medication ,  reviewing the diagnosis and confirming treatment 
adherence are highly warranted (48). 
2.2 Evidence on the role of the community pharmacist in depression care:   
The role of community pharmacists in mental health support service, 
specifically with respect to medication counselling and management, has been 
demonstrated in several studies in the literature (33, 49-55). Of note that such roles 
were also clearly defined by The American Society of Healthcare Practitioners ASHP 
and by WHO (16, 21, 23) .  
Patients who suffer from depression commonly visit community pharmacies to 
seek advice on a newly prescribed antidepressant , consult on its safety and its proper 
use , or ask for nonprescription remedies for either somatic or non-somatic symptoms 
resulting from undiagnosed depression or failure in treating depression. Treatment 
failure may underline poor follow up with physician, incompliance to regimen or 
premature dropping of antidepressant medication (35, 43). Several studies have 
demonstrated that community pharmacists can play a unique role in supporting such 
patients (56). This role underlies a set of pharmacist practices or interventions that were 
described in the literature (39), and were centered around mental health medication 
support service .These community pharmacist interventions  were shown to  improve 
consumer outcomes across different measures and  could be easily adaptable (51). An 
important example is seen in the BLOOM program that was done in Canada in 2018, 
in the context of community pharmacy mental healthcare capacity building. This 
program involved mixed-method research on the role of community pharmacist 
regarding mental health patients(57). In this program, a community pharmacist follow-
up encounter with a mental health patient happened mostly for medication optimization,  
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proved to be effective and its median duration was around 15 minutes (57). More 
specifically, in patients with depression, the provision of adequate follow up and 
medication management and counselling by pharmacists, particularly upon treatment 
initiation, can have a positive effect on patient adherence to antidepressant medications. 
It may also decrease the chance of relapse and positively influence several other mental 
health outcomes (51).Evidence on these roles will be discussed in details in the next 
sections. 
Pharmacists can greatly enhance patients’ adherence to antidepressant regimens 
through medication counselling and management. They can improve patients’ 
understanding of their mental health condition and the purpose of taking their 
antidepressants as prescribed (33, 35). Recent studies from the Kingdom of Saudi 
Arabia (KSA) and Kuwait showed that patients who were counselled on their 
antidepressant medication by a pharmacist had significantly better medication 
adherence (50), compared to those who did not receive counselling (50). In Canada, the 
BLOOM program (57), the most frequent mental healthcare care activity performed 
and the reason for patients’ follow-up meetings with the study community pharmacists 
were related to medication management. As high as 89% of the patients reportedly 
entered the program for medication optimization. Upon discharge from the program,  
78% of the patients had outcome scores indicating that the issue behind their enrollment 
in this program was “resolved” or “improved”(57) . A systematic review in Spain also 
provided evidence on the improvement of patient adherence to antidepressants. Patients 
diagnosed with depression who received collaborative care interventions that included 
pharmacists and other allied healthcare professionals had a 0.65 probability of 
remaining adherent to their medications, and that was translated to a number needed to 
treat that was equal to 7  (56, 58) .    However, it recommended more research in this 
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area, specifically outside of the USA (56). In a 2018 systematic review, medication 
management and counselling provided by pharmacists had a positive impact on patient 
adherence to antidepressant medication in adult outpatients, but no clear effect on 
clinical symptoms. This suggested a need for more longitudinal research on the 
relationships between community pharmacist interventions, patient adherence to 
treatment, and depression related clinical outcomes (53). 
Drug attitude and antidepressant treatment acceptability of depressive patients 
were significantly improved when community pharmacists provided coaching on 
depression and antidepressant medications to patients who initiated treatment by a 
primary healthcare provider (54).  
In patients initiated on an antidepressant, treatment satisfaction, general 
disease–related concerns and medication overuse beliefs were shown to improve 
significantly as a result of a community pharmacists’ intervention.  This occurred when 
community pharmacists practiced a role in assessing patients’ beliefs and knowledge 
about antidepressants using a shared decision making framework, as was seen in some 
studies (25, 26). 
Improvement of health-related quality of life was another important outcome of 
the pharmacist intervention. A systematic review done in 2017 showed that patients 
newly diagnosed with depression reported a higher health-related quality of life when 
they received focused education on depression from a community pharmacist (55). 
However, there was no difference in the severity of depression or health-related quality 
of life after 6 months (50).  
2.3 Factors affecting pharmacists’ practices in depression care: 
A key question would be, whether pharmacists are actively providing 
antidepressant counseling and what major factors are affecting pharmacists' decisions, 
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willingness and ability to play such an important role in the community setting (33). 
No extensive literature is available on that,   and most of the evidence mainly comes 
from USA and other western countries. A common finding from available studies was 
that pharmacists provided a smaller number of pharmacy services to patients with 
mental illnesses, compared to patients with other chronic diseases (59)   
 Literature focused on the main interacting factors such as the pharmacist 
attitude and stigma towards depression and mental illness in general, attitude towards 
pharmacist role in mental health care, and pharmacists’ perceived barriers against 
delivery of pharmaceutical care of mental illness at the level of community pharmacy 
(49, 60). Stigma is defined as “ a mark of shame, disgrace or disapproval which results 
in an individual being rejected, discriminated against, and excluded from participating 
in a number of different areas of society”(61). Several examples from literature explain 
how these factors may interact differently and have a resulting impact on practice. A 
cross sectional survey done in Belgium found that pharmacists’ attitudes towards 
mental illness and pharmaceutical care of mental illness to be generally positive. 
However, it showed that pharmacists’ willingness to play a role in patient counselling 
was not reflected in their current practice, specifically with patients who suffered from 
depression compared to patients with other physical conditions (60, 62). In another 
study, the majority of community pharmacists had high mental health literacy, but 
pointed out that they held some negative attitudes and perceived high stigma towards 
mental illness, which might have caused a negative impact on their provision of patient 
care for depression (63) .However, this study was limited by a low response rate that 
did not exceed 19 %. A survey was done in KSA to assess the attitudes of community 
pharmacists working at nine pharmacies that were exclusively licensed to dispense 
psychotropic medications. Results from this survey showed positive pharmacists’ 
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attitudes towards both mental illness and the provision of pharmaceutical care to 
mentally ill patients. Nevertheless, pharmacists expressed being uncomfortable 
counseling  and following-up on patients for adverse drug-related problems (64) . In a 
USA study to investigate stigma in different sectors of healthcare providers, community 
pharmacists’ perceived stigma towards depression was similar to the stigma of other  
health care providers (doctors, nurses..), but lower than that of the  general members of 
the community (49). 
  Several perceived barriers against the provision of depression care at the level 
of community pharmacy were reported in the literature (33, 59, 62, 65). Barriers against 
pharmacist’s interventions in depression may relate to the nature of a patient’s mental 
health condition, while others may relate to what pharmacists perceive as general 
barriers that originate from their professional practice setting. Some of these examples 
are the lack of private consultation space, lack of access to medical patient medical 
records, lack of referral system, and lack of time. Of note is that lack of time education 
and training, followed by lack of time, lack of privacy in the pharmacy and lack of 
access to information about patient’s health profile and medications were the most 
reported perceived barriers in the literature (62). Nevertheless, some literature has 
shown that despite the mental health education and trainings that were offered to 
healthcare students, including pharmacists, stigmatizing attitudes might have  still be 
affected their delivery of care to consumers (60, 62, 66, 67). 
In presence of such barriers, and the need to have them well addressed, evidence 
on the importance of the efforts done to overcome such barriers, specifically those 
related to organizational and environmental factors , and the sustainability of such 
efforts still needs to accumulate (68, 69). However, identifying such barriers remained 
a crucial step that drove several training programs that were able to improve depression- 
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related knowledge and attitudes of community pharmacists (41, 70, 71).  
2.4 Burden and care of depression in Qatar 
In Qatar, the 2011 Annual Health Report of the HMC s ho w ed  t h a t  
outpatient visits of the HMC Psychiatry Hospital had a 32% increase during the last 
ten years (17). A high prevalence of psychiatric morbidity in primary health care setting 
largely goes undiagnosed and consequently unmanaged (4, 17). In 2011, a study based 
on Qatar Primary Health Care Corporation (PHCC) data, which included 1660 Qatari 
patients (46.2% males and 53.8% females), showed a 36.6% overall prevalence of 
mental disorders, among which depression had the highest prevalence (13.5%) (44). In 
another study done at the PHCC-level in 2013 that examined the frequency of somatic 
symptoms and its relationship to comorbid mental disorders, found that physical 
complaints in 15.3% of the patients who visited he primary health care centers were 
associated with depression (72). The important implications of such results set an urgent 
need for further local research on mental disease risk factors, burden, treatment gaps 
and outcomes in order to generate evidence needed by policy makers (4). 
Qatar’s latest National Health Strategy has set a target to improve access  mental 
health services, aiming at 20% of care being delivered in primary and community 
sectors by 2020 (3). Qatar PHCC has identified some challenges with respect to the 
private or community sector In Qatar, such a sector of healthcare has variable quality 
of care and the unavailability of a clinical information system, which may hinder the 
implementation of specific quality measures usually needed to monitor standards of 
service delivery. Recently, new clinical guidelines for depression and anxiety were 
introduced in Qatar as a  measure to integrate care pathway between primary and 
secondary care (73).  
Qatar also set a goal to increase community awareness on mental health illness 
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and increase availability of services, while acting against stigma towards mental health 
issues in general. Additionally, the introduction of more high-quality mental health 
services in both community and inpatient settings was set as an action plan  to utilize 
adequate skill-mix of mental health professionals across all settings of care (3). HMC 
Recently introduced community based mental liaison service at one pilot center of 
PHCC, in an effort to start implementing community based model of mental health 
care.(74) 
2.5 Evidence on roles of community pharmacists in Qatar: 
Several surveys were conducted lately in Qatar to examine the current practice, 
knowledge of different disease areas, and attitude of community pharmacists towards 
practicing some pharmacy extended roles. Results from these surveys showed that 
pharmacists had a generally positive attitude towards involvement in cardiovascular 
disease (CVD) prevention(31), acute gastroenteritis management (75), and breast 
cancer awareness (76). Nevertheless, there was a clearly reported lack of needed 
knowledge and skills that reflected in their suboptimal practices in such health areas. 
Some other surveys assessed the current involvement and attitudes of community 
pharmacists about providing health promotion activities for patients with diabetes, 
asthma, and CVD as well as delivering smoking cessation counselling and intervention 
(31, 77, 78).. For example, diabetic patients were found to be mainly receiving basic 
services (traditional counselling about blood sugar lowering medications and self-
testing of blood glucose) from community pharmacists (77).  With respect to smoking 
cessation activities, pharmacists had a similar positive attitude. Moreover, a smoking 
cessation program delivered by ambulatory pharmacists in Qatar was shown to 
significantly decrease smoking rates at 3 and 6 months compared with usual care (30). 
There is a little known about whether pharmacists in Qatar are sufficiently 
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contributing to depression care. No published data in Qatar is available so far to indicate 
whether community pharmacists are keen to provide needed support for such patients, 
neither to describe their current attitudes and preparedness towards depression care, 
which appear to be important factors that are likely to affect pharmacists’ provision of 
medication management and counselling (33, 51, 59) . 
Given that stigma against mental health is a major barrier that prevents patients 
with major depression from seeking treatment (62), and that it is quite common that  
patients who remain undiagnosed complain from unexplained  somatic and non-somatic 
symptoms ,  such patients tend to frequently seek help in primary care (72, 79) and 
community pharmacies .  
Qatar had identified an urgent need for further local research on mental disease 
risk factors, outcomes, burden and treatment gaps in order to obtain evidence for 
policymaking (4).Additionally, there is a documented scarcity in local research around 
pharmacy practice pertaining to mental health, specifically in the area of community 
pharmacy practice. Hence, it would be important to explore the current practice and 
attitudes of pharmacists towards those patients. Literature has demonstrated how 
several sociodemographic factors were associated with the level and the intent to 
deliver medication management services by community pharmacists (33, 59, 62). The 
literature on the effect of such factors on stigma towards depression was also 
contradictory (80).  We envisage that, what we learn from the literature that is based in 
the western world would not fit exactly in the local context of the Gulf region, and 
hence, it would be important to explore how practices and attitudes of pharmacists 
might be different.  For example, data from USA showed that pharmacy type and 
pharmacist demographic variables such as gender, age, and years of practice were not 
significant predictors of the intent of community pharmacists to provide medication 
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therapy management services (81) . However, with the exception of gender, the effect 
of sociodemographic factors varied to a certain extent across studies done in other parts 
of the world. For example, a study that explored the current practices of community 
pharmacists in Qatar in the field of CVD showed that practices varied significantly 
depending on the type of pharmacy; i.e., whether they worked in a the outpatient 
pharmacy of a hospital, a community pharmacy of a private clinic or that located in a 
shopping mall (31). 
Based on all factors  discussed previously in this section , and due to the nature 
of depression as disease which leads to low adherence and high loss in follow up with 
physicians, our study  addressed community pharmacists working in the private sector 
only, and did not include those working in the public sector. We assume that 
pharmacists at outpatient pharmacies of the public healthcare centers are not only less 
accessible, but also have a practice that is confined to a particular profile of depressive 
patients (82). Such pharmacists mainly encounter patients who come to dispense 
medication right after a follow up with their physicians, and consequently they interact 
to a lesser extent with patients who have medication adherence issues or those who 
stopped following up with their physicians. 
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CHAPTER 3: AIM, RESEARCH QUESTIONS AND HYPOTHESIS  
3.1 Study aim and objective: 
Our study aims to investigate the role of Qatar community pharmacists’ in 
relation to depression management in community care, which has been a major public 
health issue. The objective of this study is to assess attitudes, practices and perceived 
barriers of community pharmacists in relation to depression care .This was done by 
conducting an online survey describe how community pharmacists in Qatar rate their: 
 Current practices in relation to depression care, particularly medication 
management and counselling. 
 Attitudes towards depression care.   
 Perceived barriers that might affect their performance with respect to depression 
care. 
3.2 Study hypothesis and research questions: 
           We hypothesize that community pharmacists in Qatar are willing to play a role 
in depression care and are aware of barriers against such a role. In addition, we 
hypothesize that community pharmacists’ attitudes and their socio-demographic and 
professional characteristics might be associated with their degree of practicing of 
depression care at the level of community pharmacy.  
Research questions that we would like to address are: 
• What are the current practices of Qatar community pharmacists’ in relation to 
depression care? 
• How do community pharmacists rate their attitudes towards depression and    
their role in depression care? 
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• What are their current perceived barriers against caring for patients with 
depression who visit their pharmacies? 
• How are their reported attitude towards depression, their sociodemographic and 
professional characteristics related to their current practices? 
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CHAPTER 4: METHODS 
4.1 Study design  
 This study is a cross-sectional survey targeting community pharmacists in 
Qatar. An online survey using SurveyMonkey™ software was circulated in the form of 
an email containing the survey link. In order to have more participation, pharmacists 
who submitted the survey were eligible to enter a draw to win the latest edition of   
“Lexicomp Drug Information Handbook”. Reminders were planned apriori to be sent 
on two consecutive weeks and then after one month, and responses to be collected until 
reaching the desired response rate. . We targeted a reasonable response rate of 30%.This 
was based on response rates in similar studies in literature, including surveys that were 
addressed to the same population of Qatar community pharmacists, and assessed the 
practices and attitudes of towards provision of care to patients with several non-mental 
diseases (33, 59, 62, 77, 83). 
4.2 Study population 
 All retail/community pharmacists practicing in Qatar were eligible for 
participation in the survey. There were no specified criteria for exclusion from 
enrollment in this study. Qatar MoPH has an up-to-date contact database of all 
community pharmacists practicing in Qatar (around 1200 pharmacists). This list was 
adapted with permission for use in the study. The survey email was sent to all 
pharmacists in the provided list, which corresponded to the whole population of 
licensed community pharmacists who are practicing in Qatar at the time of conducting 
the survey.  
4.3 Design of survey questionnaire 
 An inclusive literature review was conducted using PubMed, Cochrane and 
Google Scholar search engines. We used different key word combinations and included 
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meta‐analyses, randomized controlled trials, systematic reviews, clinical practice 
guidelines and review papers about pharmacist's role in depression care and mental 
health promotion, and relevant articles were adapted for development of our survey 
instrument. A questionnaire was then adapted with permission from previous studies 
that assessed the attitudes and practices of pharmacist towards depression care. Those 
studies were conducted in  KSA (64),USA (33, 59, 84),  Europe (60, 66) ,UK (85) and 
UAE (86). We sought permission to adapt the instruments used in these studies by 
contacting corresponding authors via email. All these instruments were based on valid 
items mainly adopted from The Depression Attitude Questionnaire DAQ (87) , The 
Revised DAQ Questionnaire (88), The Depression Stigma Scale (80) and the Defeat 
Depression Questionnaire (89) . 
 The draft survey was sent to a number of faculty members at the College of 
Health Sciences and The College of Pharmacy of Qatar University, who are experts in 
the subject area and in survey design. They did not follow a structured technique, but 
simply assessed whether each of the survey scale items matched the given conceptual 
domain .They also provided their comments on the survey readability, content validity, 
clarity, relevance and time to completion (90). The instrument reliability was also be 
pretested by seven community pharmacists whose responses were not included in the 
survey later. Minor modifications in the survey were applied accordingly, like 
rephrasing some item statements and adding some definitions of some of the medical 
terms used. Internal consistency and reliability were tested using Cronbach's alpha 
reliability analysis and showed high internal consistency (alpha coefficient=0.91).                 
. 
 Survey items included in the final version of the survey addressed four main 
sections (Appendix A): 
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   Section I is composed of the community pharmacists’ sociodemographic and 
pharmacy practice characteristics. Sociodemographic and pharmacy practice 
characteristics included age (60), gender, highest academic qualifications, number of 
years of practice, mental health trainings, current position in pharmacy, and personal 
experience with depression. Additionally, we included questions on the type of 
pharmacy setting, socio-economic and ethnic origin of patients who frequently visit this 
pharmacy (60, 91, 92), and the frequency of dispensing antidepressant medications at 
that pharmacy (31, 56, 59). 
 Section II is about pharmacists’ current depression-related practices. Those 
were adapted from published instruments of previous studies (33, 59) mainly in the 
context of counselling and antidepressant medication management. Pharmacists where 
asked how frequently they provided information on the symptoms, purpose, efficacy, 
side effects, and time course of their antidepressant treatment, and how often they 
managed adherence, screened, followed up or referred patients who have depression 
(33, 59, 93). 
  Section III explored pharmacists’ attitudes toward depression care. Attitudes 
are defined as “organizations of feelings and behavioral tendencies” (59). A valid 
instrument which we adapted from literature for use in this section considered attitudes 
to depression to be  composed of 4 domains; attitudes towards  causes of depression, 
attitudes towards nature and course of treatment of depression,  attitude towards patients 
with depression (66, 88), and attitude and perceptions of their professional roles (59). 
We measured attitude collectively by including items that were specific to each of those 
domains (60).Some of the items of the four domains of attitude were initially drawn 
from the Common Sense Model CSM and the Theory of Planned Behavior TPB ,two 
theoretical models that explain the relationship between individual’s attitude and his 
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practice  . Items from TPB measured self-efficacy i.e. pharmacists' confidence in their 
current scientific knowledge, their skills and their ability to communicate with patients 
who suffer depression. These items were: “ I have adequate current knowledge on 
medication therapy for major depression”, “I make it a priority to counsel patients with 
major depression on the importance of adhering to their prescribed antidepressant 
medications “, “I am comfortable to counsel patients with major depression on the 
importance of adhering to their prescribed antidepressant medications”, “I am confident 
about my ability to counsel patients with major depression on the importance of 
adhering to their prescribed antidepressant medications” and “I am interested to counsel 
patients with major depression on the importance of adhering to their prescribed 
antidepressant medications”. Items drawn from CSM measure a set of perceptions 
related to mental illness (49, 81). The set of CSM items which we used in our adapted 
instrument asked about the emotional and psychological consequences of depression, 
perceptions about the pharmacist role and its possibility of controlling and curing 
depression, about perceptions of depression as a chronic disease that is recurrent and 
episodic in nature. 
  
  Section IV asked pharmacists about their perceived barriers in relation to 
depression counseling provision (86) . The items used in this section were adapted from 
a valid instrument that measured pharmacists’ attitude towards depression care (60, 62) 
Items of this instrument were drawn from the TPB, which defined barriers as 
“organizational influences and environmental influences external to the pharmacy 
that facilitate or restrict antidepressant counselling” (33).  Examples are the lack 
of a private area for consultation, lack of time, lack of personnel, lack of needed 
knowledge and lack access to patients’ health profile.(33, 49, 59, 60, 62). 
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 To assess their depression care practices, pharmacists were asked to rate, on a 
five point Likert scale, how often they performed each of a number of activities that are 
related to depression counselling. Response categories included ‘‘Never’’, ‘‘Rarely’’, 
‘‘Sometimes’’, ‘‘Most of the time’’, and ‘‘Always’’. Similarly, a 5-point Likert scale 
“strongly agree”, “agree”, “neutral”, “disagree”, “strongly disagree” was used to 
measure the extent to which pharmacists agreed with statements related to their attitude 
towards the nature of depression, towards patients with depression and towards their 
role in depression care. As for barriers, pharmacists were provided with a list of items 
and were asked to identify which of these items they would consider a barrier to 
depression care (86). 
 Study outcomes were then measured by calculating scores of attitudes towards 
depression care and scores of self-reported practices in depression care, and by 
identifying the number of perceived barriers of respondents. 
 
4.4 Survey implementation 
 The list of 1200 community pharmacist contacts provided by the MoPH was 
screened for any duplicate or invalid email addresses where we ended up with 975 
unique email addresses. The online survey was then circulated between September and 
December 2019 using all addresses in our resultant list. Reminder emails were sent at 
1, 2 and 4 weeks intervals (94). Emails that included the survey link asked the 
pharmacists to reply by “done” any time after they submit the survey in order to include 
their email addresses in the prize draw. By doing so, we insured their individual 
responses remained unidentifiable. 
 
4.5 Ethical approval and confidentiality 
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 An explanatory statement about the aim of the survey and the confidentiality of 
collected data were included in the first page of the survey instrument (Appendix A), 
so that all pharmacists who filled survey could be considered as consented. The survey 
questionnaire was completely anonymous. Before conducting the analysis, we made 
sure to remove any identifiable information that respondents could have possibly 
included in their answers. The study was approved by the Ministry of Public Health 
MoPH of Qatar and Qatar University Institutional Review Board QU IRB (QU-IRB 
1131-E/19) (Appendix B). It was also funded by a student grant from Qatar University 
(QUST-2-CHS-2019-15). All data related to the study were saved in a password-
protected database along with all related study documentation and kept with the study 
primary investigator at Qatar University College of Health Sciences. 
4.6 Study outcomes 
 The study outcome variables are pharmacists’ self-reported practices in relation 
to depression care, self-reported attitude, and perceived barriers of community 
pharmacists in relation to depression care 
4.7 Statistical analysis 
            Descriptive analysis 
 A depression practice score was created by coding participants’ answers to each 
of the depression-related practice statements as never = 1, rarely = 2, sometimes = 3, 
usually = 4 and always =5, then adding up the scores of all practice statements to create 
a practice score for each pharmacist. The highest scores were assigned to statements 
that indicated higher levels of practice .Based on the presence of 12 statements in the 
practice scale, the summed practice score was measured on  a potential scaled score 
range  of 12 to 60 (59).  Similarly, an attitude score related to pharmacist’s attitude 
towards depression care was created by coding each attitude item as strongly agree = 
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5, agree = 4, neutral = 3, disagree =2 and strongly disagree = 1. The highest scores were 
assigned to items that indicated more positive attitude and vice versa. .Pharmacists’ 
attitude towards depression care fell under the previously mentioned four domains of 
attitude, and hence attitude scores were measured using the four corresponding 
subscales. Each of the attitude towards causes of depression subscale, attitude towards 
patients with depression subscale and attitude towards pharmacists’ role in depression 
care subscale was comprised of 11 items, while the subscale that measured attitude 
towards the course of depression was comprised 10 items ,Scores of these four 
subscales were summed to create a total attitude score for each pharmacist. Hence, the 
resultant total number of attitude items was equal to 43.Accordingly, the total attitude 
score was measured on a potential scaled score range of 43 to 215. We also added the 
total number of selected barriers to indicate a number of perceived barriers for each 
pharmacist (31, 33).  
 Descriptive statistics for respondent characteristics and responses of the full 
cohort of respondents were examined. We summarized continuous variables, such as 
scores of attitude and scores of practice, by using means and standard deviations or 
medians and interquartile ranges for variables that showed skewed distributions (95).  
For a better description and understanding of practice scores and attitude scores, we 
transformed each of them from its original scale to a scale of 1 to 5. We considered a 
total score between 3 and 4 to indicate moderately positive attitude and moderate degree 
of practice, while that higher than 4 indicated highly positive attitude or high degree of 
practice. Similarly, a total score between 2 and 3 indicated slightly negative attitude or 
poor practice, while that lower than 2 indicated very negative attitude and poor practice.  
Frequency distributions were used to describe categorical variables that defined 
baseline characteristics such as gender, country of education, pharmacy type...etc. 
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Frequency distributions were also used to describe item variables that measured 
pharmacists’ depression-care-related practices and those which measured pharmacists’ 
attitude towards depression. We similarly described the frequency of each identified 
type of barrier. Testing for reliability and internal consistency of our adapted instrument 
was done using Cronbach alpha, with an alpha coefficient of 0.91 indicating high level 
of internal consistency. 
    Plans for missing data 
 Missing data is an expected issue in self-administered surveys, where 
respondents tend to opt out from answering some of the survey questions due to 
different reasons, such as the presence of some sensitive questions or the use of lengthy 
surveys (96). Our survey had to be relatively lengthy, in order to address the several 
study outcomes and meet the study objectives. This is specifically applicable to the 
section that assessed pharmacists’ attitudes, which is a multi-faceted outcome that had 
to be measured over four domains, based on a valid instrument from literature (60). 
Additionally, the survey was self-administered, and it included demographic and 
behavioral information, which makes it more prone to have missing values and resultant 
bias. Therefore, we assessed the presence of missing values in our collected data by 
applying descriptive statistics. We also planned to explore the type of any missing data; 
i.e., whether it was missing completely at random MCAR, by applying Little’s Test for 
MCAR data. We also planned to describe the patterns and depth of such missing data 
(96). 
            Regression analysis 
 Regression analysis was then performed to assess the proposed relationships 
between the score of practices as the dependent variable, and the potential predictor 
variables: score of attitudes, sociodemographic characteristics, personal experience 
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with depression, characteristics of the pharmacy practice site and the number of 
perceived barriers.  
 Three continuous variables, which were age, the average number of daily 
prescriptions and the average percent of weekly prescriptions that contained 
antidepressants showed the presence of some outliers, so we categorized them 
according to interquartile range and clinically meaningful cut-offs (24). We also 
combined the categories of the variables, which described the pharmacist country of 
origin into three main categories:  East Mediterranean origin, South East Asian, and 
other nationalities. This was done according to WHO definition of regional groupings 
, so as to make more meaningful inferences (97). We similarly regrouped the variable 
related to the country where the pharmacist practiced previously .However, we kept 
“other GCC countries” as a separate category since these countries have a common 
profile of pharmacy practice and a healthcare system which is similar to that in Qatar, 
but which varies from that of the remaining East Mediterranean countries (28, 98). Such 
a categorization can also sort out the effect of the different levels of stigma in Qatari 
and GCC communities compared to other countries, which is proposed to have an 
impact on the extent of delivering depression care to community members (99). 
Bivariate analyses (using a univariate regression) were first conducted to 
investigate the association between depression practice score and each of the variables 
(demographics, pharmacist professional characteristics, attitudes score and barriers 
score). Variables with a p-value of 0.20 or less at the bivariate analysis level were 
included in the multivariate model (100, 101) .  
 A multivariate linear regression was then estimated using practice scores as the 
dependent variable and the potential predictors retained from the bivariate regression 
analysis. We used this model to assess the significant predictors of practice, and we 
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reported an effect size for each predictor using coefficients and confidence intervals 
.Our statistical analyses was conducted using STATA 15.1 software, and with an 
assigned a p-value of 0.05 for statistical significance. 
          Regression Diagnostics 
 Regression diagnostics were applied to explore the presence of unusual and 
influential data, assess the validity of regression assumptions (linearity, normality of 
residuals, heteroscedasticity and multi-collinearity) and assess the final model fit. We 
considered a cutoff value of 10 for assessing multi-collinearity based on evidence from 
literature (102) . 
          Bias Assessment 
 We investigated the presence of non-response bias by comparing the baseline 
characteristics of early respondents (first 20%) with those of late respondents (last 
20%), using Chi-square test of proportions. This method of response bias assessment is  
evident in literature (33, 59), and is based on the Continuum of Resistance model, which 
implies that late-responders are expected to be similar to non-respondents on the 
measures of interest (103). 
 Only a sub-cohort of the full respondent set was analyzable and could hence be 
utilized in the multiple regression analysis. Therefore, we compared the baseline 
characteristics of this regression sub-cohort with those of the full cohort of respondents 
using Chi-square test of proportions (59).  
 We also sought to assess any selection bias that would limit the generalizability 
of our study results to the whole population of 1200 community pharmacists in Qatar. 
Thus we compared some baseline characteristics of our respondent sample with what 
available to us from the MoPH data and from similar surveys that were done previously 
in Qatar. Those characteristics included pharmacist age, country of origin, years since 
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last pharmacy degree graduation, and the type of pharmacy. This kind of comparison 
had been used to assess selection bias in a similar study in literature (31) 
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CHAPTER 5: RESULTS 
5.1 Descriptive Analysis: 
 Based on the full pharmacist list provided by MoPH, and after screening it for 
duplicate emails, our mailing list included 975 unique email addresses of practicing 
community pharmacists. A total of 918 emails were successfully delivered to 
pharmacists, while 57 emails bounced back. In response to those 918 emails   , we ended 
up with 358 pharmacists filling the survey (39% response rate). Out of these 358 
returned responses, 205 were complete and had no missing data on any of the variables 
(Figure 1). 
 
 
Figure 1: Survey Flowchart 
 
 The baseline characteristics of the pharmacists who responded to our survey are 
shown in Table 1. The majority of pharmacists were from Indian origin, had a median 
age of 32 years, held a BSc in pharmacy and had practiced as a community pharmacist 
for less than 5 years. Not more than one fifth of respondents had attended a course or a 
continuous development training session about depression or mental health in general, 
over the last two years. The estimated percentage of weekly prescriptions containing an 
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antidepressant was 2%, while the majority of pharmacists (81.7%) reported that 
antidepressant prescriptions constituted up to 10% of the average weekly prescriptions 
dispensed at their pharmacy. Twelve pharmacists indicated they were not sure what 
percentage of the weekly prescriptions received at their pharmacy included 
antidepressants. Only 8.1% of the respondents indicated that they ever suffered a certain 
type of mental illness, while around one third reported having a family member or a 
friend who suffered a mental illness. Yet around 22% preferred not to disclose any 
information in that regards. 
 Six covariates had more than 5 % of missing values, which were years since last 
pharmacy degree graduation (n=19, 5.3%), age (n=25, 7.0%), average number of daily 
prescriptions (n=31, 8.7%), the percentage of weekly prescriptions that contain 
antidepressants (n=37, 10.3%), number of perceived barriers (n=83, 23.2%), and scores 
of total attitude (n=95, 26.5%). We presented an illustration of the patterns of missing 
data and its frequency distribution in Appendix C. We could see that 73 pharmacists 
contributed to the missing data on the number of perceived barriers and  scores of total 
attitude: 12 pharmacists had missing data only on scores of total attitude , 4 had missing 
data only on scores number of perceived barriers while 57 pharmacists had missing 
values on both variables. This could probably be explained  by the fact that our survey 
was conducted online, and questions which collected data on those two covariates were 
positioned in the last two sections of the survey, so sometimes survey length may cause 
participants to skip more questions towards the end of the survey and tend to submit 
the survey prematurely (104, 105). Further investigation of missing data was done, 
where result from Little’s test for MCAR was not statistically significant (Chi-Square 
= 4.75, p-value =0.09).Thus we concluded that results from our survey were not 
affected by the presence of missing data as the data was missing completely at random. 
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This means that the random subset of missing values had a similar distribution to that 
of observed values, so causes of missing-ness were not related to pharmacists’ 
characteristics or responses. We accordingly conducted our analysis using only 
complete cases with no need of imputation for missing data (96).     
 
Table 1: Pharmacists’ Baseline Socio-demographic and Professional Characteristics  
Characteristic                                      n (%) or                                                  
Median (Interquartile range) 
Gender   n=358  
   Male  212(59.7) 
   Female     143(40.3) 
  
Age (in years)   n=333 32(8)* 
   Less than30 years  119(35.7) 
   30-40 years 165(49.6) 
   Older than 40 years 49(14.7) 
  
Country of origin   n=354  
  East Mediterranean 148(42.0) 
  South East Asian 204(58.0) 
  
Country of previous practice   n=351  
  East Mediterranean 131(37.3) 
  South East Asian 202(57.6) 
 GCC country 18(5.1) 
  
Highest Academic Degree     n=354  
  Undergraduate degree 314(88.7) 
  Postgraduate degree 40(11.3) 
  
Years since last pharmacy degree  
graduation     n=339 
 
  Less than 5 years  74(21.8) 
  5-10 years 130(38.3) 
  11-15 years 66(19.5) 
  More than 15 years 39(20.4) 
 
Attended any specialized training or continuing  
education (CE) activity related to  any mental   
health topic during the last 2 years    n=354 
 
  No    277(78.2) 
  Yes 77(21.8) 
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Characteristic                                      n(%) or                                                  
Median (Interquartile range) 
Attended  any specialized training or continuing 
education (CE) activity related to depression 
during the last 2 years      n=352 
 
  No 289(82.1) 
  Yes 63(17.9) 
  
Years of experience as a community 
 pharmacist     n=351 
 
  Less than 5 years  202(57.6) 
  5-10 years 102(29.0) 
  11-15 years 28(8.0) 
  More than 15 years 19(5.4) 
  
Current position in pharmacy   n=353  
  Pharmacist in training 24(6.8) 
  Employee pharmacist 214(60.6) 
  Other 115(32.6) 
  
Type of current community/retail 
pharmacy where pharmacist is 
practicing    n=351 
 
  Pharmacy located in a shopping mall 
  or a supermarket 
189(53.8) 
  Pharmacy located in a private clinic  49(13.9) 
  Pharmacy located in a private hospital 15(4.3) 
  Street pharmacy 74(21.1) 
  Others 24(6.9) 
  
Socioeconomic class of patients  
visiting this pharmacy  n=350 
 
  Low socioeconomic class 50(14.3) 
  Middle socioeconomic class 220(62.8) 
  Upper socioeconomic class 80(22.9) 
  
Ethnicity of patients  
visiting this pharmacy  n=349 
 
  Arabs/Middle Easterners 73(20.9) 
  Asians 34(9.7) 
  A mix of all nationalities 242(69.4) 
  
Availability of a private/confidential area 
to counsel patients (in person  or over the 
phone)  n=348 
 
  No 229(65.8) 
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Characteristic                                      n (%) or                                                  
Median (Interquartile range) 
  Yes 119(34.2) 
 
Presence of a psychiatric clinic close to the 
pharmacy n=348 
 
  No 257(73.9) 
  Yes 37(10.6) 
  I don’t know 54(15.5) 
  
Number of pharmacists working in pharmacy 
during one shift   n=350 
 
 One pharmacist 263(75.1) 
 More than one pharmacist 87(24.9) 
  
Average number of prescriptions processed on  
a workday at this  pharmacy n=327 
8(16)* 
  <4 73(22.3) 
  4-8 102(31.2) 
  8-20 58(17.8) 
  >20 94(28.7) 
  
Percentage of weekly prescriptions containing  
antidepressants  n=321 
2(4)* 
  <1%    68(21.1) 
  1%-10% 204(63.6) 
  >10% 49(15.3) 
  
Pharmacist ever suffered from a mental  
illness   n=344 
 
  No 295(85.8) 
  Yes  28(8.1) 
  Prefer not to disclose 21(6.1) 
  
  
Pharmacist has a family member or friend  
with mental illness n=344   
 
 
  No 227(66.0) 
  Yes 95(27.6) 
  Prefer not to disclose 22(6.4) 
East Mediterranean countries: Jordan, Palestine, Syria, Iraq, Egypt, Sudan 
South East Asian countries: India, Philippines, Pakistan 
 GCC countries: KSA, UAE, Oman, Kuwait, Qatar or Bahrain 
*Median (Interquartile range) 
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 5.1.1 Pharmacists’ practices in relation to depression care 
The survey included 12 different activities that defined pharmacists’ practices 
in relation to counselling and medication management for patients who have depression 
(Table 2). The extent of pharmacists’ involvement in these depression care practices 
was low, (mean score=2.64, SD= 0.94,), out of a possible score of 5.Pharmacists’ 
minimum practice score was 1 and the maximum was 12. The distribution of the score 
of practice is shown in Figure 2. Internal consistency testing of this scale was done 
using Cronbach alpha which showed   high consistency (alpha coefficient=0.94). Only 
about one third of pharmacists reported being “usually” or “always “ involved with a 
range of 1-4 out of these 12 activities .The most practiced depression care activity was 
encouraging adherence to antidepressants (37.22%). This was followed by practices 
like providing information about the time course of response to antidepressant 
medication (33.19%), providing information about the purpose of treatment with 
antidepressants (33.34%) and discussing options for managing possible side effects of 
antidepressant medications (28.93%). In addition, 66.46% of pharmacists reported that 
they “rarely “or “never” screened patients for major depression or other mental illness, 
and 64.87% reported they “rarely” or “never” followed up patients who have major 
depression. 
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Figure 2: Distribution of Scores of Practice (n=314) 
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Table 2: Pharmacists’ Practices in Relation to Depression Care 
 n (%) 
How often do you perform each of the following depression care 
related activities?  
Mean 
Score* 
(SD)      Never      Rarely  Sometimes      Usually    Always 
       
Provide verbal information about major depression 
and/or about the prescribed antidepressant drug 
regimen (n=318) 
33 (10.37) 103(32.38) 109 (34.27) 41 (12.89) 32(10.06) 2.79(1.11) 
 
 
 
Provide written information/handout/guide about 
major depression and/or about the prescribed 
antidepressant drug regimen (n=318) 
104(32.70) 83(26.10) 73(22.96) 36(11.32) 22(6.92) 2.33(1.23) 
 
 
 
Provide information about symptoms and/or causes 
of major depression (n=317) 
58(18.29) 88(27.76) 100(31.56) 41(12.93) 30(9.46) 2.67(1.19) 
 
 
Provide information about the purpose of the 
antidepressant medication (n=316) 
33(10.44) 89(28.16) 88(27.85) 69(21.84) 37(11.71) 2.96(1.17) 
 
 
Provide information about the time course of 
response to antidepressant medication (n=317) 
40(12.62) 79(24.92) 92(29.03) 63(19.78) 43(13.56) 2.96(1.22) 
 
 
Discuss options for managing possible side effects 
of antidepressant medication (n=318) 
44(13.84) 81(24.47) 101(31.76) 50(15.72) 42(13.21) 2.88(1.21) 
 
 
Ask patients about potential barriers to taking the 50(15.87) 84(26.66) 93(29.53) 55(17.46) 33(10.48) 2.0(1.20) 
   
   
39 
antidepressant(s) prescribed (n=315)  
 n (%) 
How often do you perform each of the following depression care 
related activities?  
Mean 
Score* 
(SD)      Never      Rarely  Sometimes      Usually    Always 
Encourage adherence to the antidepressant regimen. 
(n=317) 
52(16.40) 71(22.40) 76(23.97) 70(22.08) 48(15.14) 2.97(1.30) 
 
 
Contact patients’ physician to adjust the prescribed 
antidepressant regimen (change dose, remove or 
add additional medications) (n=317) 
103(32.49) 93(29.34) 76(23.97) 31(9.78) 14(4.42) 2.24(1.13) 
 
 
 
Follow up patients who have major 
depression.(n=316) 
110(34.81) 95(30.06) 64(20.25) 34(10.77) 13(4.11) 2.19(1.14) 
 
       
Screen patients for major depression or other 
mental illness (n=316) 
141(44.62) 69(21.84) 68(21.52) 27(8.54) 11(3.48) 2.04(1.14) 
 
 
Refer patients to trusted mental health care 
practitioners in the community (n=317) 
64(20.19) 66 (20.82) 86 (27.13) 48 (15.14) 53(16.72) 2.87(1.35) 
 
 
Overall Mean Score of practices**                                                                                                                                                            2.64(0.94)                                                                                                                                                        
*Mean score of individual practice items out of possible score of 5, rated on a 1-5 Likert scale (1= never 2=rarely 3=sometimes, 4=usually 
5=always). Higher scores indicate more practice of depression care activities. 
**Mean score of practices for all the respondents, out of possible score of 5   
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 5.1.2 Pharmacists’ attitude towards depression care 
Pharmacists’ attitude was defined by four domains: attitude to causes of 
depression, attitude towards the nature, course and treatment of depression, attitude 
towards patients with depression, and attitude towards pharmacists’ role in depression 
care. The mean score of total attitude was estimated to be 3.41,   with standard deviation 
of 0.26, out of a maximum possible score of 5, and hence showing moderately positive 
attitudes towards depression care in general (Figure 3). Internal consistency testing of 
this scale was done using Cronbach alpha showed high consistency (alpha 
coefficient=0.90).  
 
 
Figure 3: Distribution of Scores of Total Attitudes (n=263) 
 
 
Table 3 shows the mean scores and the distribution of responses regarding pharmacist 
perceived causes of depression.  The overall mean score to this domain was 3.49, with 
a standard deviation of 0.36, out of a maximum possible score of 5, and indicating a 
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moderately positive attitude towards causes of depression.   The top two perceived 
causes of depression were stressful life style and negative life events (  87.54 % and 
85.91%). More than 70% of pharmacists agreed or strongly agreed that depression may 
be caused by psychological, biochemical and other biological factors like heredity and 
disorders of brain metabolism. At the same time, a majority agreed that depression was 
also caused by weakness of character (63.73%) and by influence of mass media 
(70.47%)  
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Table 3: Pharmacists’ Attitudes towards Causes of Major Depression 
 n (%) Mean 
Score*(SD)  What is your extent of agreement to whether each of the below is a 
cause of major depression? 
Statement Strongly     
disagree 
 Disagree 
   Neutral     Agree  
Strongly  
agree 
 
Stressful lifestyle (n=297) 10(3.37) 5(1.68) 22(7.41) 128(43.10) 132(44.44) 4.23(0.91) 
Problems with other people (n=296) 7(2.36) 14(4.73) 47(15.88) 166(56.08) 62(20.95) 3.88(0.87) 
Disorder of brain metabolism (n=298) 9(3.02) 12(4.03) 70(23.49) 130(43.62) 77(25.84) 3.85(0.95) 
Heredity (n=295) 9(3.05) 42(14.24) 88(29.83) 117(39.66) 39(13.22) 3.45(0.99) 
Environmental poisons** (n=295) 30(10.17) 110(37.29) 103(34.92) 48(16.27) 4 (1.36) 2.61(0.92) 
Influence of mass media** (n=298) 3(1.01) 6(2.01) 79(26.51) 155(52.01) 55(18.46) 2.15(0.77) 
Today’s achievement-oriented society (n=298) 5(1.68) 14(4.70) 66(22.15) 137(45.97) 76(25.50) 3.88(0.89) 
Negative life events (n=298) 8(2.68) 6(2.01) 28(9.40) 133(44.63) 122(41.28) 4.19(0.89) 
Weakness of character** (n=298) 4(1.36) 22(7.46) 81(27.45) 130(44.07) 58(19.66) 2.26(0.90) 
Biochemical causes (n=296) 1(0.34) 15(5.07) 59(19.93) 158(53.38) 64(21.28) 3.90(0.79) 
Psychological causes (n=298) 2(0.67) 7(2.35) 43(14.43) 173(58.05) 73(24.50) 4.03(0.73) 
Overall Mean score of pharmacists’ attitudes towards causes of depression***                                                                                          3.49(0.36)                                                                                          
*Mean score of individual attitude items with scores out of possible score of 5,   rated on a 1-5 Likert scale (1= strongly disagree 2=disagree 
3=neutral 4=agree 5=strongly agree). Higher scores indicate more positive attitude towards cause of disease. 
**Reverse coded items (1= strongly agree 2=agree 3=neutral 4=disagree 5=strongly disagree) are “Environmental poisons”, “Influence of mass 
media” and “weakness of character”. 
***Mean score of pharmacists’ attitudes towards causes of depression, out of possible score of 5. 
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Pharmacists’ moderately positive attitude towards the nature, course and 
treatment of depression (mean score=3.64, SD= 0.39), was evident in their responses 
on seven out of the ten items that were listed under this domain (Table 4). For example, 
more than 85% of the pharmacists agreed or strongly agreed that major depression has 
major consequences on life, can be treated , and that patients with major depression 
need support and understanding from their environment . The majority of pharmacists 
(57.85%) also agreed or strongly agreed that patients generally understand the 
counseling information delivered to them by pharmacists. While around two thirds of 
pharmacists agreed or strongly agreed that depression can improve with time and that 
antidepressants were addictive, almost half of them disagreed or strongly disagreed that 
most patients with depression get better without treatment. 
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Table 4:  Pharmacists’ Attitudes Towards the Nature, Course and Treatment Approach of Major Depression 
 n (%) Mean 
Score*(SD)  What is your extent of agreement to whether each of the 
below is a cause of major depression? 
Statement Strongly     
disagree 
 Disagree 
   Neutral     Agree  
Strongly  
agree 
Major depression is a real disease (n= 299 ) 8(2.68) 26(8.72) 41(13.77) 110(36.91) 113(37.92) 3.98(1.05) 
Major depression has major consequences on life (n=298 ) 3(1.01) 5(1.68) 29(9.72) 138(46.31) 123(41.28) 4.25(0.77) 
Major depression will improve with time (n= 296 ) 13(4.39) 32(10.81) 85(27.70) 125(42.23) 44(14.86) 2.47(1.01) 
There is a lot that patients can do to control symptoms (n= 296) 6(2.02) 15(5.05) 51(17.17) 159(53.54) 66(22.22) 3.88(0.87) 
There will be periods of depression and periods of improvement. 
(n= 297 ) 
2(0.67) 6(2.02) 46(15.49) 182(61.28) 61(20.54) 3.98(0.70) 
Antidepressant is addictive (n= 295 ) 12(4.07) 39(13.22) 68(23.05) 125(42.37) 50(17.29) 2.44(1.05) 
Major depression can be treated (n= 296 ) 4(1.35) 4(1.35) 34(11.49) 138(46.62) 116(39.19) 4.20(0.80) 
Most patients with major depression get better without treatment 
(n= 296) 32(10.81) 116(39.19) 79(26.69) 46(15.54) 23(7.77) 
3.29(1.09) 
Patients with major depression need support and understanding 
from their environment (n=297 ) 3(1.01) 8(2.69) 27(9.10) 108(36.36) 151(50.84) 4.33(0.83) 
Patients with major depression generally understand the 
counseling information I deliver to them (n=280) 
1(0.36) 11(3.93) 106(37.86) 128(45.71) 34(12.14) 3.65(0.75) 
Overall Mean Score of Pharmacists’ attitudes towards the nature, course and treatment approach of depression***                                                                                                                                    3.64(0.39) 
   
   
45 
*Mean score of individual attitude items, out of possible score of 5, with scores rated on a 1-5 Likert scale (1= strongly disagree 2=disagree 
3=neutral 4=agree 5=strongly agree). Higher scores indicate more positive attitude towards cause of disease. 
**Reverse coded items (1= strongly agree  2=agree 3=neutral 4=disagree 5=strongly disagree) are: “Major depression will improve with time”,” 
Antidepressant is addictive” , “Antidepressant can change one’s personality” , “Most patients with major depression get better without treatment” 
***Mean score of  pharmacists’ attitudes towards  nature, course and treatment approach of depression  of depression  out of possible score of 5 
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However, pharmacists had generally negative attitudes towards patients with 
depression, as this domain scored lowest among all four attitude domains (mean score= 
2.83, SD=0.37) (Table 5). The highest scoring item, which was “Anyone could suffer 
from depression”, tended to be the only positive attitude towards patients which the 
majority of pharmacist shared (81.80%). Around two thirds of pharmacists agreed or 
strongly that antidepressants could change one’s personality (63.95%), that patients 
with depression did not believe they needed medication (71.06%) and were hard to talk 
to (60.81%). All the remaining items of this domain were agreed on by almost half of 
the pharmacists. For example, 51.51% of pharmacists indicated that patients who 
suffered depression did not adhere to their medications, and 48.63% said that these 
patients were less willing to be counseled by pharmacists in comparison to patients 
without depression. In addition, around half of the respondents expressed that patients 
with major depression did not put unnecessary strain on pharmacists and were at higher 
risk for discrimination by healthcare professionals. 
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Table 5: Pharmacists’ Attitudes Towards Patients with Major Depression 
 n (%)  
 What is your extent of agreement to each of the below 
statements? 
Mean 
Score* 
(SD) Statement Strongly     
disagree 
Disagree 
Neutral Agree 
Strongly  
agree 
Patients with major depression are at higher risk for discrimination 
by healthcare professionals(n= 297 ) 
18(6.06) 50(16.84) 98(33.00) 108(36.36) 23(7.74) 3.22(1.01) 
Patients with major depression do not believe they need medication 
(n=294  ) 
4(1.36) 29(9.86) 86(29.26) 141(47.96) 34(11.56) 2.41(0.86) 
Patients with major depression do not adhere to their medication 
(n= 297 ) 
2(0.67) 35(11.78) 107(36.04) 121(40.74) 32(10.77) 2.50(0.86) 
Patients with major depression are hard to talk to (n= 296 ) 4(1.35) 37(12.50) 98(33.11) 134(45.27) 23(7.77) 2.54(0.85) 
Patients with major depression have themselves to blame (n=297)   14(4.71) 30(10.10) 106(35.69) 116(39.06) 31(10.44) 2.59(0.96) 
Patients with major depression are unreliable (n= 296 ) 15(5.07) 43(14.53) 125(42.24) 93(31.42) 20(6.76) 2.78(0.94) 
Patients with major depression ae less willing to be counseled by 
pharmacists than are patients without depression (n=296  ) 
5(1.68) 53(17.90) 94(31.78) 113(38.17) 31(10.47) 2.61(0.95) 
Anyone can suffer from major depression (n=298  ) 5(1.68) 14(4.70) 35(11.74) 142(47.65) 102(34.23) 4.08(0.89) 
Antidepressant can change one’s personality (n=294  ) 10(3.40) 29(9.86) 67(22.79) 144(48.98) 44(14.97) 2.44(1.10) 
I believe patients with major depression do not put un-necessary 
strain on me (n=280) 
4(1.43) 39(13.93) 117(41.78) 96(34.29) 24(8.57) 3.34(0.87) 
It is easy to recognize a patient who has major depression (n=297) 11(3.70) 55(18.2) 90(30.30) 116(39.06) 25(8.42) 2.70(0.98) 
Overall Mean Score attitude to patients with depression ***                                                                                                                                     2.83(0.37) 
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*Mean score of individual attitude items, out of possible score of 5, with scores rated on a 1-5 Likert scale (1= strongly disagree 2=disagree 
3=neutral 4=agree 5=strongly agree). Higher scores indicate more positive attitude towards cause of disease. 
**Reverse coded items  (1= strongly agree  2=agree 3=neutral 4=disagree 5=strongly disagree) are: “Patients with major depression do not believe 
they need medication”, ”Patients with major depression do not adhere to their medication” ,“Patients with major depression are hard to talk to”, 
“Patients with major depression have themselves to blame”, “Patients with major depression are unreliable”, ”Patients with major depression are 
less willing to be counseled by pharmacists than are patients without depression”, ‘Antidepressant can change one’s personality”, “I believe 
patients with major depression do not put un-necessary strain on me” and “It is easy to recognize a patient who has major depression. 
***Mean score of  pharmacists’ attitudes to patients with depression,  out of possible score of 5 
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As for the attitude towards pharmacists’ role in depression care(Table 6), the 
overall mean of pharmacists’ scores was the highest compared to their scores on the 3 
previous attitude domains (mean score=3.71,SD=0.48). This indicates that pharmacists 
had relatively more positive attitudes towards their role than towards depression as a 
disease or towards patients who suffer from depression.  The proportion of pharmacists 
who agreed or strongly agreed to 10 out of the 11 items in Table 6 ranged between 
38.52% and 83.93%. The highest score was for the item “I should actively support the 
recovery efforts made by individuals who suffer from major depression”, and the 
lowest score was for the item, “Patients with major depression do not want to talk about 
this with a pharmacist.” Items on interest, comfort and   confidence to counsel patients 
with major depression on the importance of adhering to their prescribed antidepressant 
medications were among these 10 highly scoring items, with proportions of pharmacists 
who agreed or strongly agreed was being 78%, 73.3% and 65.7% respectively. 
Around half of the pharmacists reported that they had adequate current knowledge 
on medication therapy for major depression. 
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Table 6: Pharmacists’ attitudes Towards Their Role in Care of Major Depression 
 n (%) 
 What is your extent of agreement to each of the below 
statements?  
Mean 
Score*(SD) 
Statement 
 
Strongly     
disagree 
Disagree 
Neutral Agree 
Strongly  
agree 
 
I should actively support the recovery efforts made by individuals who 
suffer from major depression (n=280) 
4(1.43) 2(0.71) 39(13.93) 146(52.14) 89(31.79) 4.12(0.77) 
I should advise patients on all potential side effects of antidepressant 
medications (n=280) 
3(1.07) 14(5.00) 47(16.78) 127(45.36) 89(31.79) 4.01(0.88) 
 
It is ethical for me to tell the patient what the purpose of antidepressant 
drug is (n=280)       
3(1.07) 8(2.86) 54(19.29) 135(48.21) 80(28.57) 4.00(0.83) 
I believe that physicians do not always deliver all relevant and needed 
depression related information to their patients (n=280) 
5(1.79) 32(11.43) 114(40.71) 99(35.36) 30(10.71) 3.41(0.89) 
I have adequate current knowledge on medication therapy for major 
depression (n=280) 
3(1.08) 20(7.17) 103(36.91) 128(45.88) 25(8.96) 3.54(0.79) 
I make it a priority to counsel patients with major depression on the 
importance of adhering to their prescribed antidepressant medications 
(n=277) 
3(1.08) 9(3.25) 62(22.39) 152(54.87)  51(18.41) 3.86(0.78) 
I am comfortable to counsel patients with major depression on the 
importance of adhering to their prescribed antidepressant medications 
(n=280)  
8(2.86) 11(3.93) 58(20.71) 140(50.00) 63(22.5) 3.84(0.93) 
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I am confident about my ability to counsel patients with major 
depression on the importance of adhering to their prescribed 
antidepressant medications (n=280) 
7(2.50) 12(4.29) 79(28.21) 131(46.79) 51(18.21) 3.72(0.91) 
I am interested to counsel patients with major depression on the 
importance of adhering to their prescribed antidepressant medications 
(n=279) 
4 (1.43) 6 (2.15) 59(21.15) 132(47.31) 78(27.96) 3.97(0.98) 
Major depression is a disease like any other (e.g. , asthma, diabetes) 
 (n= 297 ) 
17 (5.7) 55(18.5) 57(19.2) 103(34.7) 65(21.9) 3.48(1.18) 
Patients with major depression do not want to talk about this with a 
pharmacist  
(n=296  ) 
14(4.73) 61(20.61) 107(36.14) 84(28.38) 30(10.14) 2.81(1.02) 
Overall Mean Score attitude towards pharmacist role in care of major depression***                                                                                                           3.71(0.48)                                                                                                                                     
 
*Mean score of individual attitude items, out of possible score of 5, with scores rated on a 1-5 Likert scale (1= strongly disagree 2=disagree 3=neutral 
4=agree 5=strongly agree). Higher scores indicate more positive attitude towards cause of disease. 
**A reversely coded item (1= strongly agree  2=agree 3=neutral 4=disagree 5=strongly disagree) is “Patients with major depression do not want to talk 
about this with a pharmacist” 
***Mean score of  pharmacists’ attitudes towards pharmacist role in care of major depression out of possible score of 5 
 
52 
  
 
 
A summary of the attitude scale and subscales is presented in Table 7. Across 
the 4 domains used to assess pharmacists’ total attitudes, the relatively most positive 
pharmacists’ attitude   was  shown   towards their role in depression care  ( mean score= 
3.71 , SD=0.48 )   ,  while  their attitude towards patients with depression was the least 
positive ( mean score= 2.83 , SD=0.37 )  . Pharmacists’ attitude towards the nature, 
course and treatment of depression and towards causes of depression were moderately 
positive, with mean scores of 3.64   and 3.49 and standard deviations of 0.39 and 0.36 
respectively. All these scores were measured out of a total possible score of 5. 
 
Table 7: Descriptive Summary of Attitude Scales 
Scale Mean (SD) 
 
Minimum 
score 
Maximum 
score 
Attitude towards causes of depression 
(11 items) 
3.49 (0.36) 1.90 4.27 
    
Attitude towards the nature, course 
and treatment of depression (10 items) 
 3.64 (0.39)  2.20 4.60 
    
Attitude towards patients  
with depression(11 items) 
 2.83  (0.37)  1.72 4.27 
    
Attitude towards role in depression 
care (11 items) 
3.71 (0.48)  2.27 4.90 
    
Total attitudes towards depression care   
(43 items) 
3.41 (0.26) 2.46 4.18 
    
SD Standard Deviation 
*Scores displayed were transformed from their original scales to a scale of 1-5  
 
 
 5.1.3 Pharmacists’ perceived barriers towards depression care 
The survey asked pharmacists whether they agreed or disagreed to each of eight 
listed perceived barriers, in order to calculate a number of perceived barriers per 
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pharmacist. Pharmacists’ perceived a median number of barriers that was equal to 6 
(based on skewness of distribution), with an interquartile range of 2, and a range 
between 0 and 8 (Figure 4). The majority of pharmacists agreed on all the items in the 
list of perceived barriers which our survey proposed, except for the item on “sensitivity 
to ethnic/cultural differences”, where slightly less than half of the pharmacists 
considered this as a barrier against provision of care to depressed patients at the level 
of community pharmacy. The top four perceived barriers were lack of access to 
patient’s medical profiles (83.21%), lack of patient’s insight on major depression and 
the importance of treatment (81.85%), lack of needed knowledge and training on mental 
health (79.63%) and lack of private setting in the pharmacy (74.73%) (Table 8). 
 
 
 Figure 4: Distribution of the Number of Perceived Barriers (n=275) 
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Table 8: Pharmacists Perceived Barriers against Care of Major Depression   
Barrier n (%)        
  
Lack of access to patients' medical profiles (n=268) 223 (83.21) 
Lack of patient's insight on major depression and the importance of 
treatment (n=270) 
221 (81.85) 
Lack of knowledge /training on mental health (n=270) 215 (79.63) 
Lack of a private setting in the pharmacy (n=273) 204 (74.73) 
Lack of needed time (n=273) 193 (70.70) 
Lack of clear clinical guidelines (n=272) 188 (69.12) 
Shortage of personnel (n=272) 180 (66.18) 
Sensitivity to ethnic/cultural differences (n=274) 132 (48.18) 
 
5.2 Regression Analysis: 
Bivariate analysis             
Bivariate analyses using a univariate linear regression was  first conducted to 
investigate the association between depression practice score and each of the 
independent variables: sociodemographic and professional characteristics of 
pharmacists, characteristics of practice setting, personal experience with depression , 
scores of attitude and the number of perceived barriers (Table 9). Out of the 22-
predictor variables that were used in our survey, 14 variables appeared to be associated 
with practice scores using a statistical significance level of p-value ≤ 0.20. These 
variables were attitudes towards depression care, the number of perceived barriers 
towards depression care, pharmacists’ sociodemographic characteristics (gender ,age) 
,  pharmacists’ professional characteristics  ( country  of previous practice  ,  years since 
last pharmacy degree graduation,  having attended a training or course on depression 
topic in the last 2 years ), having ever suffered a mental illness , having a family member 
or a friend with mental illness,  and some characteristics of practice settings ( type of 
pharmacy setting , ethnicity of patients attending this pharmacy ,  presence of a 
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psychiatric clinic close to the pharmacy , the percentage of weekly prescriptions that 
included antidepressant , and the presence of a private counselling area). Based on 
literature about the confounding effect of some variables and on the significance of 
association with the outcome at the bivariate analyses, all these 14 variables were used 
to estimate a multiple linear regression model. 
 
Table 9: Bivariate Linear Regression of the association between the Score of Practices 
and Potential Predictor Variables             
Variable                                      Coefficient 95% CI* P-value 
Gender      
    Male   Reference   
   Female -5.81 (-8.32, -3.31) 
 
<0.001 
    
Age (in years)       
   Less than 30 years  Reference   
   30-40 years -4.35 (-7.16 ,-1.53) <0.01 
   Older than 40 years -6.69 (-10.64, -2.74) <0.01 
    
Country of origin       
  East Mediterranean Reference   
  South East Asian 1.01 (-1.55, 3.59) 
 
 0.43 
    
Country of previous practice       
  East Mediterranean Reference   
  South East Asian 1.50   (1.14,  4.15) 0.26 
  GCC country -4.15  (-10.05, 1.75)  0.16 
    
Highest Academic Degree         
  Undergraduate degree Reference   
  Postgraduate degree -0.76 (-4.86, 3.33) 0.71 
    
Years since last pharmacy degree 
graduation    
   
 Less than 5 years  Reference   
 5-10 years -0.87 (-4.22, 2.47)   0.60 
 11-15 years -7.26 (-11.13, -3.39)  <0.001 
 More than 15 years -5.50 (-9.32, -1.68) <0.01 
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Variable                                      Coefficient 95% CI* P-value 
Attended any specialized training or 
continuing education (CE) activity  
related to any mental health topic  
during the last 2 years? 
   
  No    Reference   
  Yes 1.37 (-1.67, 4.42) 
 
0.37 
Attended  any specialized training or 
continuing 
education (CE) activity related to 
depression during the last 2 years       
   
  No Reference   
  Yes 3.91 (0.65, 7.16) 0.01 
    
Years of experience as a community 
 pharmacist      
   
  Less than 5 years  Reference   
  5-10 years -0.34 (-3.22, 2.53) 0.81 
  11-15 years -2.16 (-6.83, 2.49) 0.36 
  More than 15 years -5.71  (-11.52, 0.08) 0.05 
    
Current position in pharmacy       
 Pharmacist in training Reference   
Employee pharmacist 0.54 (-4.58, 5.67)  0.83 
 Other 1.44 (-3.88,  6.78) 
 
 0.59 
Type of current community/retail 
pharmacy where pharmacist is 
practicing     
   
  Pharmacy located in a 
  private   hospital 
Reference   
  Pharmacy located in a  
  private clinic  
-2.91  (-9.97,  4.14)  0.41 
  Pharmacy located in a  
 shopping mall or a supermarket 
5.13 (-1.32,  11.59) 0.11 
  Street pharmacy 4.15 (-2.63, 10.93) 0.23 
 Other 0.035 (-7.94,  8.01) 0.99 
    
Socioeconomic class of patients  
visiting this pharmacy  
   
  Low socioeconomic class Reference   
  Middle socioeconomic class -1.37 (-4.99,  2.25)  0.54  
  Upper socioeconomic class -1.31 (-5.47,  2.85) 
 
 0.53 
Ethnicity of patients  
visiting this pharmacy   
   
  Arabs/Middle Easterners Reference   
  Asians 3.37 (-1.35,  8.11)  0.16 
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Variable                                      Coefficient          95% CI* P-value 
 
Variable                                    Coefficient          95% CI* P-value 
 
Variable                                    Coefficient          95% CI* P-value 
 
Variable                    Co fficient          95% CI* P-value 
 
  A mix of all nationalities 4.80 (1.71,  7.89) 0.002 
 
Availability of a private/confidential 
area to counsel patients (in person  
or over the phone)          
   
  No Reference   
  Yes 3.88 (1.23,  6.54) 0.004 
 
Presence of a psychiatric clinic close 
to the pharmacy    
   
  No Reference   
  Yes 6.49 (2.46  10.52) 0.002 
  I don’t know -0.88 (-4.33  2.56)  0.61 
    
Number of pharmacists working in 
pharmacy during one shift   
   
 One pharmacist Reference   
 More than one pharmacist 0.13 (-2.82, 3.10)   0.92 
    
Average number of prescriptions 
processed on a workday at this  
pharmacy   
   
  <4 Reference   
 4-8 -0.12 (-3.75, 3.50)  0.94 
  8-20 -1.75 (-5.17, 1.66)  0.31 
  >20 -2.93 (-6.79, 0.92) 
 
 0.13 
Percentage of weekly prescriptions 
containing  
antidepressants  
   
 <1%    Reference   
 1%-10% 4.19 (0.91, 7.47) 0.01 
  >10% 6.97 (2.68, 11.25) 0.002 
    
Pharmacist ever suffered from 
a mental illness    
   
 No Reference   
 Yes  -3.23  (-7.70, 1.23) 0.15 
 Prefer not to disclose -6.24 (-11.49, -0.98) 0.02 
    
Pharmacist has a family member or 
friend with mental illness       
   
  No Reference   
  Yes 2.49 (-0.30, 5.30) 0.08 
  Prefer not to disclose -3.11 (-8.09, 1.86) 0.21 
    
Pharmacist scores of total attitude 
towards depression 
 0.27 (0.15, 0.38) <0.001 
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Multiple linear regression 
Results from the multiple regression model are shown in Table 10.  Pharmacists’ 
level variables that showed a p-value < 0.05 were considered to have a statistically 
significant association with practice scores of attitude.  Pharmacists’ practice of 
depression care showed a small but statistically significant association with 
pharmacists’ attitudes towards depression care. The score of practice increased by 0.22 
units with every unit increase in attitude score (95%CI =0.09 to 0.35, p=0.001), 
controlling effects for the sociodemographic, professional characteristics of 
pharmacists, those of practice site, and score of barriers. Practice scores also increased 
with the increasing percentage of weekly prescriptions that contained antidepressants, 
with marginal statistical significance (p=0.05). However, practice scores decreased 
with the number of years since last pharmacy degree graduation , where pharmacists 
who graduated within the past 5 years had significantly higher scores of practice 
compared to those who did not (p = 0.02). Female pharmacists showed significantly 
lower involvement in depression care practices compared to male pharmacists, practice 
scored lowered by =4.36 (95% CI =-7.46 to -1.26, p<0.01). Pharmacists who reported 
to having a psychiatric clinic close by their site of practice were more involved in 
depression care. Their scores of practices were statistically significantly higher by 7.63 
units compared to those who reported not to have one (p=0.01). Similarly, the presence 
of a private consultation area in the pharmacy was strongly associated with delivering 
depression care. Pharmacists who reported having a private consultation area produced 
Number of pharmacist’s perceived 
barriers 
-0.78      
     
 (-1.44, -0.11)    0.02     
 
 
*95% Confidence Interval 
East Mediterranean countries: Jordan, Palestine, Syria, Iraq, Egypt, Sudan 
South East Asian countries: India, Philippines, Pakistan 
GCC countries: KSA, UAE, Oman, Kuwait, Qatar or Bahrain 
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significantly higher scores of practice by 3.39 units, compared to those who did not 
(p=0.03). There was also a marginally statistically significant association between the 
type of pharmacy and the extent of delivery of depression care. Pharmacists who 
delivered depression care most were the pharmacists working in a pharmacy located in 
a shopping mall, compared to those who worked in the private pharmacy of a hospital, 
who showed the lowest scores of practice among all (p=0.05).  
 
Table 10: Multiple Linear Regression of the Association between the Scores of 
Practices and Potential Predictor Variables (N=205)         
Variable                                            Coefficient                  95% CI*       P-value** 
Gender      
    Male   Reference   
   Female -4.36 (-7.46,  -1.26) 
 
0.006 
Age (in years)       
   Less than 30 years  Reference   
   30-40 years 0.02 (-4.47,  4.47)  0.99 
   Older than 40 years 0.26 (-6.85, 7.38)  0.94 
    
Country of previous practice       
  East Mediterranean Reference   
  South East Asian  1.74 (-1.49 , 4.99)  0.28 
  GCC country -4.04 (-10.96,  2.87)  0.25 
    
Years since last pharmacy degree 
graduation    
   
  Less than 5 years  Reference   
  5-10 years -2.53 (-6.93, 1.86) 0.25 
  11-15 years -7.51 (-13.28, -1.74) 0.01 
 More than 15 years -8.22 (-15.10, -1.35) 0.01 
    
Attended  any specialized training or 
continuing 
education (CE) activity related to 
depression during the last 2 years       
   
  No Reference   
 Yes   2.25 (-1.56,  5.87)  0.25 
    
Type of current community/retail 
pharmacy where pharmacist is 
practicing     
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Variable                                            Coefficient                  95% CI*       P-value** 
  Pharmacy located in a  
  private hospital          
Reference    
   Pharmacy located in a  
   private clinic  
 2.58 (-6.71, 11.88)  0.58 
  Pharmacy located in a  
  shopping mall or a supermarket 
 6.83 (-1.91, 15.59) 0.12 
  Street pharmacy  5.59 (-3.49, 14.46) 0.21 
  Other  -0.12 (-10.75, 10.51) 0.98 
    
Ethnicity of patients  
visiting this pharmacy   
   
  Arabs/Middle Easterners Reference   
  Asians  3.66 (-2.45, 9.79) 0.23 
    
  A mix of all nationalities   2.27 (-1.37, 5.92)  0.22 
    
Availability of a private/confidential 
area to counsel patients (in person  
or over the phone)          
   
  No Reference   
  Yes  3.39 (0.20, 6.59) 0.03 
 
Presence of a psychiatric clinic  
close to the pharmacy    
   
  No Reference   
  Yes  7.63 (2.54, 12.71) 0.003 
  I don’t know  1.52 (-2.56, 5.61) 0.46 
    
Percentage of weekly prescriptions 
containing antidepressants  
   
 <1%    Reference   
  1%-10%   2.47 (-1.33, 6.28)  0.20 
  >10%   6.35 (1.81, 11.52)  0.01 
    
Pharmacist ever suffered from 
 a mental illness    
   
  No Reference   
   Yes   -2.75 (-8.98, 3.48)  0.38 
   Prefer not to disclose  -2.47 (-9.06,  4.11)  0.45 
    
Pharmacist has a family member or 
friend with mental illness       
   
  No Reference   
  Yes   3.20 (-0.32,  6.74)  0.07 
  Prefer not to disclose  -0.13 (-6.23,  5.96)  0.96 
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Variable                                            Coefficient                  95% CI*       P-value** 
Pharmacist scores of total attitude 
towards depression 
  0.22 (0.09,  0.35)  0.001 
    
Number of pharmacist’s perceived 
barriers 
 -0.17      
     
(-0.95,  0.60)  0.65     
 
 
 
*95% Confidence Interval 
**p-value <0.05 is considered as statistically significant 
East Mediterranean countries: Jordan, Palestine, Syria, Iraq, Egypt, Sudan 
South East Asian countries: India, Philippines, Pakistan 
GCC countries: KSA, UAE, Oman, Kuwait, Qatar or Bahrain 
 
5.3 Regression Diagnostics: 
Regression diagnostics using normality of residuals analysis showed that 
residuals were normally distributed, as shown in Appendix D, Figure 5. Tests for 
homogeneity and residuals versus predictor plot showed no violation to the assumption 
constant variance (Breusch- Pegan test p value = 0.30). Regression diagnostics also 
showed the absence of multi-collinearity as variance inflation factor (VIF) was <10 for 
all the variables (102). Our model was correctly specified, with a p-value of the squared 
predictor= 0.81, indicating that there was no specification error. 
5.4 Results of Bias Assessment:  
Non-response bias assessment 
The results of Chi-square tests showed all showed no statistically significant 
differences between early respondents and late respondents, except for the percentage 
of prescriptions that contained antidepressants (p value = 0.002).We concluded that no 
important differences in baseline characteristics existed between early and late 
responders. However, pharmacists who worked in a pharmacy that was more involved 
in dispensing antidepressant medications seemed to have responded earlier to our 
survey (Appendix E).    
Selection bias assessment 
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 We compared some baseline characteristics of our respondent sample with those 
from similar surveys that were done previously in Qatar. In a survey conducted in 2018 
by Hajj et al, the mean age of Qatar community pharmacists was 35 years compared to 
32 years in our study. In the same 2018 survey, the highest percentage (88%) of 
pharmacists were from Egypt and India (77).This is also similar to the percentages by 
nationality that we collected in our study before we regrouped them into the two main 
categories; i.e., the East Mediterranean and South East Asian origin categories. 
Pharmacists from India and Egypt summed up to 74.2% of our total respondents. In the 
same 2018 survey by Hajj et al, the vast majority of pharmacists had attained their 
degree in the past 5-15 years (61%), mainly worked in community pharmacies of 
shopping malls (53%), while only 25% practiced in outpatient pharmacies of hospitals. 
There was a similar trend in the proportions of the baseline characteristics of our 
respondents. Up to 78% of our respondents had attained their degree in the past 5-15 
years, and a lower proportion of them practiced in hospital and private clinics (13.96 
and 4.257% respectively), compared to the proportion of those who worked in 
pharmacies of shopping malls and in street pharmacies (53% and 21.08%, respectively). 
Moreover, our observed distribution of pharmacists according to pharmacy types also 
compared well with what data available on Qatar Council of Healthcare Practitioners 
(QCHP) website about the distribution of Qatar community pharmacies (26). 
We also checked whether the complete case cohort of 205 respondents, which 
was analyzable, differed in baseline characteristics from the full respondent cohort of 
358 pharmacists. No important differences in baseline characteristics were found 
between the (Appendix F). Although we found one statistically significant difference 
with respect to the average number of daily prescriptions, where pharmacists in the 
multiple regression sub-cohort reported a higher average of daily prescriptions, this 
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variable was not significantly associated with practice in the bivariate analysis and was 
not included in the final model based on which we built our results.  
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CHAPTER 6: DISCUSSION 
6.1 Key Findings from this study: 
Our objectives in this population survey were to explore the current practices, 
attitudes and perceived barriers against delivery of depression care at the level of 
community pharmacy in Qatar, and what factors predicted the provision of depression 
counselling and medication management services.  
Our results showed that Qatar community pharmacists were not actively 
involved in any of the depression related activities which were described in literature 
as potential extended roles, and which fall beyond traditional dispensing of 
medications. Not more than one third of Qatar pharmacists were involved with any type 
of the listed depression care practices, and the relatively most practiced depression care 
activity was encouraging adherence to antidepressants (37.22%). This clearly shows 
that pharmacists are not providing even the basic pharmacy services needed by patients 
with major depression.  These results are similar to findings of a study that was done in 
Belgium (62) and in USA (33) In 200, a survey in Belgium compared the attitudes and 
self-reported practices with depressed patients to those with patients suffering other 
physical conditions in a sample of 69 community pharmacists. A low level of practice 
was demonstrated, and was much lower than that reported about non-mental health 
patients. Although 87% of pharmacists strongly agreed that they should be providing 
information on symptoms, causes or treatment of depression, only 17% of tem reported 
applying such practice with most or all their patients. The situation was not much 
different in another USA survey. In this survey of 118 community pharmacists 
conducted in Alabama, USA (33) findings regarding most of the depression related 
practices were comparable to our results and to those of the Belgian study .Community 
pharmacists had almost the same low level of practices regarding providing the needed 
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information to patients with depression and also regarding other depression related 
practices. .Only one third of them said they discussed options for managing adverse 
effects. S Such results from Qatar can be expected, since some local data  showed that 
community pharmacists were also minimally practicing their extended roles in the field 
of several other chronic diseases, including CVD care, diabetes care, and smoking 
cessation services (31, 106). However, their level of involvement in those physical 
health conditions was higher than their involvement in depression care that was 
reported in our study. For example, diabetic patients were found to be mainly receiving 
basic services (basic counselling about anti-diabetic medications and blood glucose 
self-testing) from community pharmacists (77).  Qatar pharmacists were also not 
heavily involved in health promotion for patients with CVD (31). Although the majority 
reported explaining to patients about the appropriate time for taking antihypertensive 
medications and about their common adverse effects, only half of them indicated they 
usually review the medication refill history or provide adherence interventions to those 
patients. 
 Importantly, pharmacists’ low involvement in depression care practices can be 
explained by the presence of organizational and environmental barriers related to the 
healthcare system in Qatar and in the Middle East region (29) .Examples are the lack 
of access to medical records, absence of referral system and lack of pharmacists’ 
knowledge about mental health topics. In our study, the majority of community 
pharmacists agreed on the presence of at least six of these barriers. The top four 
perceived barriers were lack of access to patient’s medical profiles, lack of patient’s 
insight on major depression and the importance of treatment, lack of the needed 
knowledge and training on mental health and lack pf private setting in the pharmacy. 
The same set of perceived barriers were seen in a 2016 cross-sectional study which 
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conducted a survey to assess Qatar community pharmacist's perceived barriers to 
counseling patients with diabetes and those with asthma , as well as assessed 
pharmacists’ current counselling practices  using simulated patient approach (78).  In 
another study that assessed their preparedness for medication use review (MUR), 
community pharmacists in Qatar were found to be  knowledgeable about the concept 
of MUR , however, some important deficiencies still warranted enhancing their 
education (24) . Our results regarding perceived barriers are also consistent with data 
from KSA and UAE (64, 86).  We investigated the effect of the increasing number of 
barriers on the scores of practices .However, our multivariate model, that controlled for 
all possible confounders did not show a significant association between the number of 
barriers and the scores of depression related practices. A similar result was seen in the 
study by Cannon et al, where the organizational and environmental barriers against 
depression care were tested in two separate models, and accounted for only 2% of the 
variance in self-reported antidepressant counselling scores, controlling for pharmacy 
characteristics and previous training on depression (33). 
Low levels of practices can also be explained by the higher levels of stigma 
towards mental health in the in the Arab region (99, 107). Stigma towards mental illness 
at the level of the general population as well as at the level of healthcare practitioners 
was investigated in several studies in the Arab region (32, 64, 65, 99, 107-110) . A 
systematic review showed evidence of high levels of stigma towards mental health 
treatments in the Arab world (99).Another study on stigma towards mental illness was 
done in a sample of university students  in Qatar. It showed that students had some  
beliefs which reflected poor mental health literacy and hence high stigma, such as 
beliefs that "medications to treat mental illness can cause addiction", "mental illness is 
not like any other illness", or that "mental illness is a punishment from God" (108). Our 
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study assessed the current attitudes of a population of community pharmacists, and our 
findings suggested that pharmacists had a relatively positive attitude towards the nature, 
causes and the course of treatment of depression as well as towards their role in 
depression care, but a negative attitude towards patients with depression. Pharmacists’ 
most positive attitude was expressed towards their role in providing depression care, 
where their scores reflected relatively high self-efficacy and positive perceptions of the 
importance of supporting patients with depression. This goes in accordance with 
findings from a study that was most recently published in Qatar (65) . This study 
provided local evidence on the attitude of Qatar primary healthcare practitioners 
towards providing mental health care to their patients. It suggested that primary care 
practitioners and pharmacists in Qatar perceived that people with mental health 
illnesses received suboptimal care for their medical comorbidities. It also recommended 
the importance of collaborative practice and shared responsibilities with patients’ 
family members in order to improve the mental and physical health of patients with 
mental illnesses. However, in a  survey conducted in KSA , pharmacists had positive 
attitudes to both mental illness and providing care to patients with mental illness, but 
they expressed being uncomfortable counseling  and following-up on patients for 
adverse drug-related problems (64).    
In our study, pharmacists expressed a relatively more negative attitude towards 
patients with depression compared to that towards depression as a disease or towards 
their role in managing its treatment. This may reflect their high levels of stigma towards 
these patients. We can compare such findings to those from Scheerder et al 2009, which 
assessed the attitudes of community pharmacists using the same four attitude domains 
that we used in our study.  This study found that a more optimistic attitude toward the 
nature and course of depression was associated with a higher acceptance of 
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pharmacists’ role in depression care, but   contrary to our study findings, with a more 
positive attitude towards patients with depression (60). This could be possibly due to 
cultural differences in the level of stigma against mental health, which has been shown 
to be high in the Arab countries (99). 
  In addition, this study was able to find a statistically significant positive 
association between pharmacists’ attitudes towards depression and their current 
depression-related practices (effect size estimate= 0.22, 95%CI = (0.09-0.35), 
p=0.001). This also goes in accordance with results from other studies (33, 59). 
Giannetti et al found that higher pharmacists’ stigma was associated with lower 
willingness and ability to perform depression counselling, and this willingness was 
directly associated with the  current self- reported  mental health related services (59). 
The same study also showed that pharmacists who were more involved with medication 
management services, in general, had lower stigma levels towards mental illness. 
Additionally, evidence from current literature shows that community pharmacists’ 
perceived stigma towards depression was similar to the stigma of other types of health 
providers, but lower than that reported with general members of the community(49).  
Our study survey collected data on several sociodemographic and professional 
characteristics of the pharmacists and their practice site, as the literature suggested they 
may be associated, to different extents, with the provision of depression care as well as 
with attitude and stigma towards depression and mental health in general (80) .  
One of the most important sociodemographic predictors of pharmacy practice 
in depression care in our study was gender, where female pharmacists showed 
significantly lower involvement in depression care as compared to male pharmacists 
(effect size estimate=-4.36,  95%CI=-7.46, -1.26 ,  p<0.001). This can be explained 
from literature, where females held higher stigmatizing views towards depression 
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(111). The result is also consistent with findings from a study that assessed pharmacists’ 
practices in relation to providing health promotional activities for patients with CVD 
(31). Based on our survey results, neither age, education level nor previous training on 
depression were significant predictors of pharmacist practices. Evidence on the strength 
and significance of these associations varied in literature, as those variables were more 
established as direct predictors of attitude rather than of current practice (31, 33, 59, 60, 
62, 80, 112). It was obvious from our study that pharmacists’ lack of knowledge was 
accompanied by a very low involvement in trainings related to depression. Only half 
of the pharmacists reported that they had adequate current knowledge on 
medication therapy for major depression, more than 70 % agreed that lack of 
knowledge was a barrier to their provision to depression care at the level of 
community pharmacy. Additionally, not more than 20 % reported they had attended 
any training on any mental health topic in the past two years. Literature has shown 
that attending courses or trainings on depression was positively associated with 
confidence and intent to provide depression care related services in USA community 
pharmacists (33). The same study found no significant association between 
pharmacists’ age and their willingness to provide depression care. In a Belgian study, 
positive attitudes of pharmacists towards depression care were not reflected in their 
current practices due to a lack of adequate education in the field of mental health (62). 
Contradictory results were found regarding the effect of age were found in a another 
study, where older age of pharmacists was associated with more pessimistic views 
towards the course of depression and its treatment, and was associated with 
pharmacists’ negative attitudes towards patients who suffered depression (60).   
Among the several pharmacists’ professional characteristics that we included in 
our study, the number of years since last pharmacy degree graduation was the only 
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characteristic associated with pharmacists’ practices regarding depression care. In our 
study, the majority of respondent pharmacists received their pharmacy degree within 
less than 10 years from the time of conducting the survey, and those who graduated 
within the past 5 years had significantly higher scores of practice compared to those 
who did not  (p = 0.02), independent of their age. Of note is that we had also investigated 
any association between pharmacists’ score of practice and the number of years they 
had been practicing as community pharmacists. However, our results were not able to 
establish such association .We were also not able to find a statistical correlation 
between the number of years in practice and the number of years since the last pharmacy 
degree graduation. In contrast,   findings from the study by Giannetti et al showed that 
pharmacists who had practiced community pharmacy for longer periods were less 
willing and less comfortable to provide mental health care services to their patients 
(59). In conclusion, we can better interpret our findings of the effect of pharmacist 
graduation date on the extent of delivering depression care in the context of the new 
changes in pharmacy curricula, and to the fact that their increased focus on extended 
pharmacy roles and collaborative care is relatively new. Pharmacy curricula in the Arab 
world recently started, to varying extents, to focus more on empowering pharmacy 
students and offering them more trainings  related to their role in mental illness and 
mental health promotion (98).     
As for practice site characteristics, our results showed that four properties of the 
pharmacy had a statistically significant association with pharmacists’ delivery of 
depression care. These were the presence of a private consultation area, the proximity 
of a psychiatric clinic, the type of pharmacy and the size of antidepressant prescription, 
as measured by the percentage of weekly prescriptions, which included antidepressant. 
 The level of pharmacists’ involvement in depression counselling and 
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medication management was significantly higher when a private area was present in 
the pharmacy (p=0.03), and this goes in accordance with several studies (20, 31, 77, 78, 
106) . An explanation of this would be that the presence of such a private space to 
counsel patients, whether in private or over the phone, would allow for more 
confidentiality, and could promote more comfortable interaction between pharmacists 
and patients. This would be specifically true in the context of mental health, where high 
stigma levels would require more privacy whenever a patient comes to seek advice on 
a mental health issue or on his/her prescribed mental health treatment regimens (3, 99). 
Our results showed the presence of a psychiatric clinic close by the pharmacy 
was significantly associated with delivering depression care by pharmacists. 
Pharmacists who reported working in the proximity of a psychiatric clinic had scores 
of practices  that were statistically significantly higher by 7.63 units  compared to cores 
of those of their counterparts , controlling for the size of antidepressant prescriptions at 
that pharmacy (p=0.003). However, we did not find any literature that studied whether 
the extent of delivering depression care was related , independently from of rate of 
dispensing of antidepressants,  to practicing in a pharmacy site that is geographically 
close to a specialized psychiatric clinic .We can think about this factor as being a proxy 
to more contact with patients who have psychiatric diagnoses. It is possible that more 
patients with mental illness would be visiting pharmacies that are nearby psychiatric 
clinics, and hence pharmacists practicing there might be in more contact with those 
patients, compared to pharmacists practicing at a further geographical distance from 
such clinics. Prior contact with patients who suffer depression has been demonstrated 
to impact attitudes towards depression as a mental health condition (80) . However, our 
survey did not directly collect information on the frequency of contact with depressed 
patients, and this remains to be a point that warrants further investigation.  
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Our survey revealed that up to 75% of community pharmacists worked in a 
pharmacy located in a shopping mall or in a street pharmacy. This goes in accordance 
with data on the MoPH website and that data provided in the MoPH list of pharmacists. 
In the latter,  numbers showed that the majority of community pharmacists in Qatar 
were practicing in pharmacies located inside shopping mall pharmacies or street 
pharmacies .We also found that  pharmacy type had an overall marginally significant 
association with  pharmacists’ depression care practices (p=0.05). Pharmacists who 
worked in a pharmacy located in a shopping mall or a street pharmacy tended to have 
higher scores of practice compared to those working in private hospital outpatient 
pharmacies. Looking at examples from literature done abroad, we found conflicting 
results .In one cross sectional survey in USA, the intent of  pharmacists to provide 
medication therapy management (MTM) services did not statistically differ across 
pharmacy types (81, 112). However, different results were seen in a meta-analysis of 
studies done in Europe, which compared the extent of pharmacists’ involvement in 
depression care across different settings. It showed that pharmacists in outpatient 
hospital pharmacies  practiced less depression counselling and antidepressant 
management, but there was a high level of heterogeneity in these studies, and was 
attributed to the smaller number of pharmacists from the hospital and primary care were 
involved in the studies (56) . Our results were also compatible with the conclusions of 
this meta-analysis concerning the issue of the small number of hospital pharmacists. 
They were also consistent with previous research in Qatar in the context of community 
pharmacy practice in relation to CVD, were there was significantly higher practice by 
the community and ambulatory pharmacists compared to hospital pharmacists (31). 
Of note is that the reported pharmacy size, as indicated by the number of daily 
prescriptions, was relatively low in our survey , with reported median number of eight 
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daily dispensed prescriptions .This number was lower than what was reported in other 
studies done in Qatar and UAE (31, 83) (113) .  At the same time, results from our 
regression analysis also showed pharmacy size was not significantly associated with 
the practice. This was inconsistent with the results form a USA study, where authors 
assessed the factors associated with the provision of mental health services at 
community pharmacies. They considered that pharmacists whose practice setting had 
high rates of prescription dispensing practiced more MTM,   and their study results 
showed that higher provision of   MTM was associated with higher degrees of 
willingness, comfort and confidence to provide depression care (59).  
Hence,  we can say that within the private pharmacy sector which our study 
addressed, community pharmacies that had the highest rates of dispensing prescription 
medications might mostly be located in private clinics or outpatient departments of 
private hospitals, which is similar to what was reported in previous research (113). We 
can also conclude that due to the  small number of private clinic pharmacists and 
outpatient hospital pharmacists in Qatar, our study wasn’t able to detect a possible 
effect of pharmacy size on the extent of pharmacists’ practice on depression care . 
On the other hand, our study found a trend increase in pharmacists’ depression-
related practices with the increase in the size of antidepressant prescriptions, controlling 
for all other baseline characteristics, including controlling for the presence of a 
psychiatric clinic in the proximity of the pharmacy. However this result had marginal 
statistical significance (p=0.05), which could be attributed to the low percentage of 
antidepressants among all prescriptions. Up to 63 % of pharmacists reported that 
antidepressants accounted for only between 1% and 10 % of the total weekly 
prescriptions dispensed at their pharmacy. 
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Interestingly, and in line with other studies, our findings showed that while there 
was lower self-reported depression care provision by pharmacists who reported that 
they had once suffered a mental illness, but higher self-reported depression care 
provision by pharmacists who had a family member or a friend with a mental illness. 
Although those both results from our model lacked statistical significance, we could 
see that such finding coincided with findings from other literature. Having suffered 
depression was associated with high levels of personal stigma towards depression, and 
was associated with negative attitudes towards depression(80). Experience with 
depression, as a measure of perceived stigma, had a positive association with both 
pharmacists’ attitudes and practices (59). A summary of all the key findings from our 
study is presented in Table 11.
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Table 11: Summary of  Key Findings From Our Study 
1. Qatar community pharmacists were minimally involved in depression-related activities.  
2. Lack of access to patients’ medical profiles, lack of patient’s insight on major depression and the importance of treatment, lack of the 
needed knowledge and training on mental health and lack of private setting in the pharmacy were the top four perceived barriers 
towards pharmacists’ practice in relation to depression. 
3. Pharmacists reported a lack of knowledge about medication management of major depression, and that only 20 % of them had attended 
a training on a mental health topic in the past two years 
4. Pharmacists reported a relatively positive attitude towards depression as a disease, but a negative attitude towards patients with 
depression. A more positive attitude was associated with higher current practice in relation to depression. 
5. Female pharmacists and pharmacists who worked in outpatient pharmacies of hospitals and private clinics were significantly less 
involved in depression care as compared to their counterparts.  
6. Pharmacists who graduated within the past 5 years, those who reported to having a private counselling area in their pharmacy, and 
those who reported having a psychiatric clinic close to their pharmacy were significantly more involved in delivering depression care 
services compared to those who did not. 
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6.2 Study Strengths and Future Implications: 
This is the first study conducted in Qatar to explore the current practices and the 
potential factors that might influence the involvement of Qatar community pharmacists 
in playing a role in depression .The survey was sent to all the target population using a 
well-defined and up-to-date sampling frame. The response rate of 39%, which is above 
the average compared to similar electronic surveys targeting similar audiences in 
several other studies (33, 59, 60, 63, 77, 91). Results from our study can help in 
improving our understanding of the current situation of community pharmacy practice 
in the field of depression care, and may serve as a baseline for further local studies. 
This is basically important due to the differences in the healthcare system between 
Qatar and Western countries where most of the research on this topic was conducted. 
Our results also show that there is room for improvement in the quality of health care 
provision for patients with mental health... Another important challenge would be that 
Qatar pharmacists, like other primary healthcare providers, are less trained and less 
socialized to communicate effectively with individuals with severe mental illness, 
compared to pharmacists in western countries. This can be attributed to differences in 
the social norms between countries in the Arab region compared to those in the west. 
Hence, several challenging steps have to be taken in that direction by policy makers. 
For example, shared practical trainings that involve direct contact with patients who are 
being managed for their depression can improve both pharmacist depression stigma and 
their knowledge on the disease. It can as well improve the skills that are needed for 
efficient delivery of antidepressant medication management and counselling (23, 114-
116). Some campaigns that aimed to improve the involvement of community 
pharmacists with depression care were also  run in Denmark and Australia (23). Future 
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research should plan for training programs and evaluate their impact on improving not 
only the knowledge but more importantly the pharmacists’ attitudes and decrease their 
stigma towards  patients who suffer from depression .This will offer the much needed 
enhancement in the practice of this important, yet under-represented, sample of the 
healthcare sector. Additionally, future studies may provide local evidence of how Qatar 
community pharmacists can utilize their expertise of counselling and medication 
management in the field of depression care and how this would improve patients’ 
outcomes. This is especially crucial when dealing with patients who are newly initiated 
on antidepressants, and those who fail to follow up with their physicians or get the 
proper advice regarding the importance of adhering to their prescribed antidepressant 
regimen. Results from this study also shed light on the importance of providing more 
continuous education activities for community pharmacists in the field of depression. 
They also highlight the need expressed by community pharmacists regarding access to 
patient medical profiles, as this issue was one of their top perceived barriers against 
practicing depression medication counselling and management. Currently, access to 
medical profile of patients is only available to community pharmacists who work in the 
outpatient pharmacy of private hospitals and those who work in pharmacies in private 
polyclinics. These pharmacists constitute a small proportion of the whole population of 
community pharmacists in Qatar (26). Providing such access to pharmacists working 
in all community pharmacists needs action from policy makers, and might be 
potentially driven by the current Qatar National Health Strategy. One of the goals set 
by this strategy states that the provision of healthcare by the private sector remains to 
be significant opportunity area and one of the MoPH key considerations (3). Our study 
can add to the efforts done currently to increase involvement and collaboration of non–
mental healthcare workers in depression care, and to improve pharmacy practice in 
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Qatar.  It is also clearly aligned with Qatar’s national healthcare strategy on mental 
health which targets higher engagement of the private health sector (3). 
6.3 Study Limitations: 
Our study has some limitations. First, it is a cross-sectional survey, hence does 
not allow us to establish causation. Second, it is a self-reported survey, so there is a 
possibility of social desirability bias, and our study was not designed to assess such 
type of bias. Hence, pharmacists’ current attitudes and practices in relation to 
depression care might have been overestimated. We cannot be sure how well our 
sample of respondents represented the total population of community pharmacists in 
Qatar in terms of geographical areas where the respondents practiced. However, we 
were able to compare some other baseline characteristics of our respondent sample with 
those from the MoPH data and from similar surveys that were done previously in Qatar, 
and we found no major differences. On the other hand, limited by the survey design, 
we did not fully assess factors like current knowledge or communication skills of 
pharmacists, which could have added better understanding of their attitudes and 
practices. We might have also missed some other potential environmental variables 
such as financial reimbursement for the extended pharmacy role , and collaboration 
with other healthcare providers, which could have demonstrated an impact on the 
association between organizational barriers and the delivery of depression care (28). 
Finally, findings from this study cannot be extrapolated to pharmacists that work in 
ambulatory pharmacies of PHCC and HMC.  We did not include those pharmacists in 
our survey due to the main differences in their type of practice. More importantly, major 
differences exist between the healthcare system in the governmental sector and the 
private sector regarding access to patient profiles and different modes of dispensing, as 
this is limited to predefined formularies and to filling and refilling of prescriptions, as 
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well as differences in the accessibility of those pharmacists by patients.  This would 
warrant future research that targets them separately, and provides data on their attitude 
and extent of their involvement in depression-related practices.  
6.4 Conclusion: 
 Our study demonstrated that there is a need to improve community pharmacists’ 
attitudes to depression care, as a way to empower them to enhance their currently 
suboptimal practice in the field. Qatar has taken many important steps towards 
improving health care provision in general. In the light of scarcity of local data relating 
to the extent of involvement of pharmacists in mental health care, specifically those 
working in the private sector, we believe that the results of our study will be providing 
an evidence-base for future longitudinal studies. This is specifically applicable to the 
current context in Qatar, at a time when mental health issue is considered as one of the 
top priority areas in the National Strategies, and which MoPH policymakers are 
focusing on. 
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APPENDICES 
Appendix A: Survey questionnaire 
 
1. 
You are cordially invited to fill out a survey where we would like to know more 
regarding your professional experience with care for major depression at the level 
of the community pharmacy where you are currently practicing. 
What your participation involves: we are asking you to answer some questions 
about your opinions and practices with regard to major depression. It will take 
about 10 minutes to complete the survey. 
In recognition of your time and effort, and upon submitting this survey, you will 
enter a draw to be one of four winners of the latest edition of Drug Information 
Handbook, 2019 . 
Benefits to you or to others which might be reasonably expected from this 
research: 
This survey is part of a research study at Qatar University. By submitting this 
survey, you will help us study the value of expanded pharmacy services to improve 
pharmacy practice in this country. 
Some important information that you need to know: 
1. Your participation in this survey is entirely voluntary. You may withdraw from 
the study at any time, even if you have begun answering questions. 
2. Data from this survey will be handled in a confidential manner in line with strict 
protection rules and guidelines of Qatar University. No information regarding 
your name or contact information will be disclosed. 
3. This study has been approved by the Qatar University Institutional Review 
Board (QU-IRB 1131-E/19). 
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4. If you have any questions about this study, please contact Ms. Rula Shami, 
Qatar University, College of Health Sciences <rulashami@qu.edu.qa> 
(+974)44036661 or (+974)334050267 or Qatar University IRB <QU-
IRB@qu.edu.qa> (+974) 4403-3333. 
By clicking “submit” at the end of the survey, we understand that you have read 
and understood the consent form. 
 
Section I: Pharmacist's socio-demographic and professional characteristics 
First, we would like to know some basic information about you. Would you please 
answer the following questions to help us better interpret the survey responses? 
Please select the appropriate answer for each of the questions below: 
1. What is your gender? 
 Female 
 Male 
2. What is your age (in years)? .................................................. 
3. What is your country of origin? 
 Qatar 
 Egypt 
 India 
 Jordan 
 Palestine 
 Philippines 
 Sudan 
 Syria 
 Other (please specify) 
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4. Beside your current practice in Qatar, in which countries did you practice pharmacy 
previously? (Please choose all that apply)? 
 Egypt 
 India 
 Jordan 
 Syria 
 Palestine 
 Philippines 
 Sudan 
 Other GCC country (KSA, UAE, Oman, Kuwait or Bahrain) 
 No previous practice outside Qatar 
 Other (please specify) 
5. Please indicate your highest academic qualification. 
 B Pharm/BSc Pharm 
 M Pharm 
 MSc Pharm 
 Pharm D 
 Ph.D. 
 Other (please specify) 
6. Please indicate the year of your last pharmacy degree graduation …………………. 
7. During the last 2 years, have you attended any specialized training or continuing 
education (CE) activity related to any mental health topic? 
 Yes 
 No 
 If your answer is "Yes', please add more details………………………………………. 
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8. During the last 2 years, have you attended any training or continuing education (CE) 
activity related to major depression? 
 Yes 
 No 
9. For how many years have you been practicing as a community/retail pharmacist in 
Qatar? 
 Less than 5 years 
 5-10 years 
 11-15 years 
 16-20 years 
 More than 20 years 
10. Which of the following best describes your position in the pharmacy? 
 Pharmacy owner 
 Employee pharmacist 
 Pharmacist in training 
 Pharmacy manager/supervisor 
 Other (please specify) 
11. Which of the following best describes the community/retail pharmacy where you 
are currently practicing? 
 Pharmacy located in a shopping mall or supermarket 
 Pharmacy located in a private clinic 
 Pharmacy located in a private hospital 
 Pharmacy located in a gas station 
 Other (please specify) 
12. Based on their level of education and income (socioeconomic level), the majority 
 98 
of patients/customers visiting your pharmacy generally belong to: 
 Low socioeconomic class 
 Middle socioeconomic class 
 Upper socioeconomic class 
13. The majority of patients/customers visiting your pharmacy are mainly: 
 Arabs/Middle Easterners 
 Asians 
 Westerners ( Europeans, Americans) 
 A mix of all nationalities 
14. On average, how many pharmacists work in your community pharmacy during one 
shift? 
 One pharmacist 
 More than one pharmacist 
15. Is there a psychiatric clinic close to your pharmacy? 
 Yes 
 No 
 I don’t know 
16. Do you have a private/confidential area available in your pharmacy to counsel 
patients (in person or over the phone)? 
 Yes 
 No 
17. On average, how many prescriptions does your community pharmacy process on a 
workday? 
..................................... 
18. On average, what percentage of total prescriptions in a given week are specifically 
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antidepressants prescriptions? 
.................................... 
19. Have you ever suffered from major depression or any other mental illness? 
 Yes 
 No 
 Prefer not to disclose 
20. Do you have any personal experiences with major depression or any other mental 
illness? (e.g friend, family)? 
 Yes 
 No 
 Prefer not to disclose 
 
Section II: Pharmacists’ practices in antidepressant management and counselling 
of major depression 
Major depression, also known simply as depression, is a mental disorder 
characterized by at least two weeks of low mood and loss of interest in normally 
enjoyable activities. 
We would like to know about your current professional practices in relation to 
major depression. 
21. How often do you perform the following activities related to antidepressant 
medication management and counseling of patients who have major depression visiting 
your pharmacy? 
Please select one appropriate answer for each question in the table below. 
How often do you… 
       never       rarely  sometimes       usually      always 
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 Provide verbal information  about major depression and/or about the  prescribed  
antidepressant drug regimen. 
 Provide written information/handout/guide about major depression and/or about 
the prescribed antidepressant drug regimen. 
 Provide information about symptoms and/or causes of major depression. 
 Provide information about the purpose of the antidepressant medication. 
 Provide information about the time course of response to antidepressant 
medication. 
 Discuss options for managing possible side effects of antidepressant 
medication. 
 Ask patients about potential barriers to taking the antidepressant(s) prescribed. 
 Encourage adherence to the antidepressant regimen. 
 Contact patients’physician to adjust the prescribed antidepressant regimen 
(change dose, remove or add additional medications) 
 Follow up patients who have major depression. 
 Screen patients for major depression or other mental illness 
 Refer patients to trusted mental health care practitioners in the community 
 
Section III Pharmacist's attitude towards major depression and patients with 
major depression. 
We are interested in knowing your general attitudes towards major depression 
and patients with major depression. 
22. Please select the appropriate box to indicate your extent of agreement with each of 
the below statements, in relation to what might cause major depression: 
                    strongly disagree     disagree     neutral     agree     strongly agree 
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 Stressful lifestyle 
 Problems with other people 
 Disorder of brain metabolism 
 Heredity 
 Environmental poisons 
 Influence of mass media 
 Today’s achievement oriented society (a society that overlooks failure and 
idealizes success) 
 Negative life events (sudden dramatic life events e.g., death of a spouse, loss of 
a job..etc) 
 Weakness of character 
 Biochemical causes (neurotransmitter imbalances) 
 Psychological causes (dysfunction in the state of emotion, thought and 
behavior) 
Comments: ……………………………………………………………………………... 
23. Please select the appropriate box to indicate your extent of agreement with each of 
the below statements, in relation to major depression: 
             strongly disagree     disagree     neutral     agree     strongly agree  
 Major depression is a real disease 
 Major depression has major consequences on life. 
 Anyone can suffer from major depression. 
 Major depression will improve with time. 
 There is a lot that patients can do to control symptoms. 
 There will be periods of depression and periods of improvement. 
 Antidepressant is addictive. 
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 Antidepressant can change one’s personality. 
 Major depression is a disease like any other (e.g , asthma, diabetes). 
 Major depression can be treated. 
 Most patients with major depression get better without treatment. 
24. Please put a tick in the appropriate box to indicate your extent of agreement with 
each statement below, in relation to patients who suffer from major depression : 
              strongly disagree     disagree     neutral     agree     strongly agree 
 It is easy to recognize a patient who has major depression 
 Patients with major depression are at higher risk for discrimination by 
healthcare professionals 
 Patients with major depression do not believe they need medication 
 Patients with major depression do not adhere to their medication 
 Patients with major depression are hard to talk to 
 Patients with major depression have themselves to blame 
 Patients with major depression are unreliable 
 Patients with major depression need support and understanding from their 
environment 
 Patients with major depression do not want to talk about this with a pharmacist 
 Patients with major depression are less willing to be counseled by pharmacists 
than are patients without depression 
 
5. Section IV: Pharmacist attitude towards his/her role in major depression 
We are interested in knowing your general attitudes towards your role as a 
pharmacist in major depression counseling and medication management. 
25. Please select the appropriate box to indicate your extent of agreement with each 
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statement below, in relation to your role in major depression care 
        strongly disagree     disagree     neutral     agree     strongly agree 
 I believe patients with major depression do not put un-necessary strain on me. 
 I should actively support the recovery efforts made by individuals who suffer 
from major depression. 
 I should advise patients on all potential side effects of antidepressant 
medications. 
 It is ethical for me to tell the patient what the purpose of antidepressant drug is. 
 Patients with major depression generally understand the counseling information 
I deliver to them 
 I believe that physicians do not always deliver all relevant and needed 
depression –related information to their patients 
 I have adequate current knowledge on medication therapy for major depression. 
 I make it a priority to counsel patients with major depression on the importance 
of adhering to their prescribed antidepressant medications 
 I am comfortable to counsel patients with major depression on the importance 
of adhering to their prescribed antidepressant medications 
 I am confident about my ability to counsel patients with major depression on 
the importance of adhering to their prescribed antidepressant medications 
 I am interested to counsel patients with major depression on the importance of 
adhering to their prescribed antidepressant medications 
 
6. Section V: Pharmacist's perceived barriers towards his role in major depression 
We are interested in knowing more about barriers against your role as a 
pharmacist in major depression counselling and medication management. 
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26. Please select the appropriate box to indicate your agreement whether each of the 
statements below is a barrier that prevents you from counseling and managing 
medications for patients with major depression. 
                    I agree     I don't agree 
 I am sensitive to ethnic/cultural differences. 
 Lack of a private setting in the pharmacy. 
 Lack of needed time. 
 Shortage of personnel. 
 Lack of clear clinical guidelines. 
 Lack of access to patients' medical profiles. 
 Lack of needed knowledge and training on mental health. 
 Lack of patient's insight on major depression and the importance of treatment . 
 
Please state any other barriers which you may consider but were not listed in the 
above:……………………………………………………………………………. 
27. Please feel free to write down any comments or thoughts you would like to express 
in relation to the care of depression at the level of community pharmacy. 
……………………………………………………………………………………. 
Now you reached the end of the survey. 
Thank you for your time and effort! 
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Appendix B: QU IRB Approval Letter 
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Appendix C: Tabulated Patterns and Numbers of Missing Values 
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Years since last 
pharmacy 
degree 
graduation 
Age 
 
 
 
Average number of 
daily prescriptions 
 
Percentage of weekly 
prescriptions that 
contain antidepressants 
Number of 
perceived 
barriers 
Score of total 
attitude 
 # of 
cases* 
% of 
cases 
         
             184 51 
    X       18 14 
          X  12 5 
        X X  51 4 
        X    4 3 
  X          12 3 
      X       15 3 
X            10 2 
    X  X X  6 1 
           
19(5.3)** 25(7.0)** 31(8.7)** 37(10.3)** 83(23.2)** 95(26.5)**    
         
X indicates missing values 
Patterns with less than 1% cases and variables that are missing at less than 5% are not displayed in this table 
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*Number of participants with a specific pattern of missing data 
**Number of missing values (% missing values) 
Variables are sorted on missing patterns 
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Appendix D: Regression Diagnostics 
 
 
 
   Figure 5: Kernel density plot of residuals of practice scores 
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Appendix E: Assessment of Non-response Bias  
 
(Difference in the baseline characteristic between early and late responders) 
 
Baseline Characteristic n % 
(First 20% of 
respondents)  
n % 
(Last 20% of 
respondents) 
P value 
    
Gender      0.17 
   Male  34   45.33 41   54.67  
   Female   
  
37   56.92       28   43.08  
    
Age (in years)      0.23 
   Less than30 years   24     61.54            15    38.46       
   30-40 years  32    49.23 33   50.77  
   Older than 40 years 12     41.38 17   58.62  
    
Country of origin      0.86 
  East Mediterranean 33    50.77 32   49.23  
  South East Asian 37    49.33 38   50.67  
    
Country of previous practice      0.91 
  East Mediterranean 28   48.28 30   51.72  
  South East Asian 36   50.70 35  49.30  
 GCC country 6     54.55  5   45.45  
    
Highest Academic Degree       0.17 
  Undergraduate degree 59  47.97 64  52.03  
  Postgraduate degree 11   68.75 5    31.25  
    
Years since last pharmacy 
degree  
graduation     
  0.70 
 Less than 5 years  15   57.69 11    42.31  
 5-10 years 27   51.92 25    48.08  
 11-15 years 11    52.38 10    47.62  
 More than 15 years 16    43.24 21     56.76  
    
Attended any specialized 
training or continuing  
education (CE) activity related 
to  any mental   
health topic during the last 2 
years     
  0.56 
  No    53     51.46 50    48.54  
  Yes 17     45.95 20   54.05     
Attended  any specialized 
training or continuing 
  0.86 
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education (CE) activity related 
to depression 
during the last 2 years       
  No 55    50.00 55    50.00  
  Yes 14    48.28 15    51.72  
    
Years of experience as a 
community 
 pharmacist      
  0.42 
  Less than 5 years  35    50.00 35   50.00  
  5-10 years 20    46.51 23   53.49  
  11-15 years 5      38.46 8    61.54  
  More than 15 years 9      69.23 4    30.77  
    
Current position in pharmacy      0.59 
 Pharmacist in training 3      75.00  1    25.00  
 Employee pharmacist 43    49.43 44   50.57  
 Other 24    48.98 25   51.02  
    
Type of current 
community/retail 
pharmacy where pharmacist is 
practicing     
  0.81 
  Pharmacy located in a 
shopping mall 
  or a supermarket 
3    42.86 4     57.14  
  Pharmacy located in a private 
clinic  
9    39.13 14    60.87  
  Pharmacy located in a private 
hospital 
34   53.13 30    46.88  
  Street pharmacy 17   51.52 16    48.48  
  Others 7     53.85 6     46.15  
    
Socioeconomic class of patients  
visiting this pharmacy   
  0.84 
  Low socioeconomic class 8    44.44 
 
10  55.56  
  Middle socioeconomic class 41   50.00 41  50.00  
  Upper socioeconomic class 20   52.63 18   47.37  
    
Ethnicity of patients  
visiting this pharmacy   
  0.82 
  Arabs/Middle Easterners 14   45.16 17    54.84  
  Asians 5     50.00 5      50.00  
  A mix of all nationalities 50    51.55 47     48.45  
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Availability of a 
private/confidential area 
to counsel patients (in person  or 
over the 
phone)        
  0.29 
  No 40   46.51 46   53.49  
  Yes 29    55.77 23    44.23  
 
Presence of a psychiatric clinic 
close to the pharmacy    
  0.99 
  No 51  50.50 50   49.50  
  Yes 8     50.00 8    50.00  
  I don’t know 10   50.00 10  50.00  
    
Number of pharmacists working 
in pharmacy during one shift    
  0.78 
 One pharmacist 50  50.00 50    50.00  
More than one pharmacist 20  52.72 18     47.37  
    
Average number of prescriptions 
processed on  
a workday at this  pharmacy  
  0.002 
 <4 29    74.36 10  25.64  
 4-8 10    43.48 13   56.52  
8-20 17   44.74 21  55.26  
>20 10    31.25 22  68.75  
    
Percentage of weekly 
prescriptions containing  
antidepressants      
  0.4 
<1%    16   59.26 11    40.74  
1%-10% 36   46.75 41   53.25  
>10% 14   58.33 10   41.67  
    
Pharmacist ever suffered from 
a mental  
illness   
  0.95 
  No 59   49.58 60   50.42  
  Yes  4     50.00 4    50.00      
  Prefer not to disclose 4     44.44 5    55.56  
    
Pharmacist has a family member 
or friend  
with mental illness      
  
  0.45 
 
  No 46    52.87 41    47.13  
  Yes 17    42.50 23    57.50  
 Prefer not to disclose 3      37.50 5     62.50  
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Appendix F: Comparison of the baseline characteristic of the full cohort of 
respondents with those of the sub-cohort which was used in the final multiple 
regression model. 
 
Baseline Characteristic n (%) 
(Full cohort of 
respondents   
n (%) 
(Sub cohort of 
respondents 
that was 
included in 
regression 
,N=205) 
P value  
    
Gender      0.73 
   Male  88    41.51 124   58.49  
   Female  62    41.25 81     56.64  
    
Age (in years)      0.23 
   Less than30 years  50    42.02 69     57.98  
   30-40 years 56    33.94 109   66.06  
   Older than 40 years 22    44.90 27     55.10  
    
Country of origin      0.46 
  East Mediterranean 66   44.59 82    59.31  
  South East Asian 83   42.33 121  57.67  
    
Country of previous practice      0.60 
  East Mediterranean 59   45.04 72    54.96  
  South East Asian 80   36.60 122  60.40  
 GCC country 7     38.89 11    61.11  
    
Highest Academic Degree       0.25 
  Undergraduate degree 135   42.99     179  57.01  
  Postgraduate degree 13     33.33 26    66.67  
    
Years since last pharmacy 
degree  
graduation     
  0.38 
 Less than 5 years  24    32.43 50   67.57  
 5-10 years 57    48.85 73   56.12  
 11-15 years 34    36.36 42   63.64  
 More than 15 years 29    42.03 40   57.97  
    
Attended any specialized training 
or continuing  
education (CE) activity related to  
any mental   
health topic during the last 2 
years     
  0.37 
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  No    120    43.32 157   56.68  
  Yes 29      37.66 48     62.34  
Attended  any specialized 
training or continuing 
education (CE) activity related to 
depression 
during the last 2 years       
  0.93 
  No 121   41.87 168  58.13  
  Yes 26     41.27 37    58.73  
    
Years of experience as a 
community 
 pharmacist      
  0.95 
  Less than 5 years  87    43.07 115  56.93  
  5-10 years 41    40.20 61    59.80  
  11-15 years 11   39.29 17    60.71  
  More than 15 years 8     42.11 22    57.89  
    
Current position in pharmacy      0.47 
 Pharmacist in training 10   41.67 14   58.33  
 Employee pharmacist 95   44. 39 119  55.61  
 Other 43   37.39 72    62.61  
    
Type of current 
community/retail 
pharmacy where pharmacist is 
practicing     
  0.72 
  Pharmacy located in a shopping 
mall 
  or a supermarket 
8     53.33 
 
7   57.14  
  Pharmacy located in a private 
clinic  
21   42.86 28   57.14  
  Pharmacy located in a private 
hospital 
74   39.15 115  60.85  
  Street pharmacy 31   41.89 43    58.11  
  Others 12   50.00 12   50.00  
    
Socioeconomic class of patients  
visiting this pharmacy   
  0.41 
  Low socioeconomic class 22    44.00 28   56.00  
  Middle socioeconomic class 95    43.18 125  56.82  
  Upper socioeconomic class 28    35.00 53    65.00  
    
Ethnicity of patients  
visiting this pharmacy   
  0.91 
  Arabs/Middle Easterners 29     39.73 44    60.27  
  Asians 15     44.12 19    55.88  
  A mix of all nationalities 100   41.32 142  58.68  
 115 
    
Availability of a 
private/confidential area 
to counsel patients (in person  or 
over the 
phone)        
  0.16 
  No 88   38.43 141  61.56  
  Yes 55   46.22 64    53.78  
 
Presence of a psychiatric clinic 
close to the pharmacy    
  0.99 
  No 106  41.25 151  58.75  
  Yes 15    40.74 22    59.46  
  I don’t know 22    40.74 32    59.26  
    
Number of pharmacists working 
in pharmacy during one shift    
  0.85 
 One pharmacist 109   41.44 154   58.56  
More than one pharmacist 37     42.53 50     57.47  
    
Average number of prescriptions 
processed on  
a workday at this  pharmacy  
  0.01 
 <4 46   48.94 48    65.75  
 4-8 25   34.25 48    65.75  
8-20 52   50.98 50    49.02  
>20 17  29.31 41    70.69  
    
Percentage of weekly 
prescriptions containing  
antidepressants      
  0.26 
<1%    30  44.12 38    55.88  
1%-10% 71  34.80 133  65.20  
>10% 15  30.61 34    69.39  
    
Pharmacist ever suffered from a 
mental  
illness   
  0.65 
  No 119  40.34 176  66.67  
  Yes  13   46.43 15    53.57  
  Prefer not to disclose 7     33.33 14    66.67  
    
Pharmacist has a family member 
or friend  
with mental illness      
  
  0.43 
  No 94  41.41 133  58.59  
  Yes 39  41.05 56   58.95  
 Prefer not to disclose 6    27.27 16   72.73  
 
 
